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Abstract 
Depression is characterised by high prevalence and complex, heterogeneous psychopathology. At the 
level of aetio-pathology, considerable research effort has been invested to identify specific gene 
polymorphisms associated with increased depression prevalence. Genome-wide association studies 
have not identified any risk polymorphisms, and candidate gene case-control studies have identified 
a small number of risk polymorphisms. It is increasingly recognised that interaction between 
genotype and environmental factors (GxE), notably stressful life events, is the more realistic unit of 
depression aetio-pathology, with GxE evidence described for a small number of risk polymorphisms. 
An important complementary approach has been to describe genes exhibiting brain region-specific 
expression changes in depression. Mouse models of depression informed by the human evidence 
allow for the study of causality, but to-date have also yielded limited insights into depression aetio-
pathology. This review of the translational evidence integrates human and mouse research 
approaches and evidence. It also makes specific recommendations in terms of how future research in 
human and mouse should be designed in order to deliver evidence for depression aetio-pathology 
and thereby to inform the development of novel and improved antidepressant treatments.    
Keywords: Depression; Psychopathology; Aetio-pathology; Gene polymorphism; Gene-environment; 
Stress; Expression; Mouse model  
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1. Introduction 
Major depressive disorder (hereafter depression) is the most prevalent disease of the central 
nervous system (CNS) and is one of the ten leading global causes of disease burden (Lopez et al., 
2006). In the absence of a definitive understanding of its pathophysiology, depression is diagnosed 
exclusively on the basis of symptoms, course and outcome. According to the major diagnostic system 
for psychiatry (APA, 2000), depression constitutes one or both of the core symptoms, depressed 
mood (sadness, emptiness) and anhedonia (loss of interest or pleasure). The core symptoms must co-
occur with at least four of the common symptoms, namely weight loss, insomnia, psychomotor 
retardation, fatigue, feelings of worthlessness/guilt, diminished ability to think/concentrate, 
recurrent thoughts of death or suicide, and suicide attempt/plan, for at least two weeks. Therefore, 
depression is a disease defined by a heterogeneous constellation of symptoms that are quite 
uninformative relative to the psychological dysfunctions that underlie them. The latter, in turn, are 
poorly understood in terms of their mediating pathophysiological processes at circuitry, cellular and 
molecular levels, and there is currently no pathophysiology input to the diagnosis. For the two core 
symptoms, depressed mood and anhedonia, neuropsychological dysfunction can be attributed, 
respectively, to hyper-sensitivity of the brain’s punishment system and hypo-sensitivity of the brain’s 
reward system (Pryce and Seifritz, 2011). Dysfunctional emotional-cognitive processing of punishing 
(aversive) stimuli/events is, at least in broad terms, a neuropsychopathology common to both 
depression and anxiety disorders e.g. generalized anxiety disorder. As would be expected therefore, 
there is a high prevalence of anxiety disorders in patients diagnosed with depression (APA, 2000). 
 Given the above situation, then an increased understanding of the genetics of depression is 
clearly vitally important. At the same time, it needs to be accepted that, given the heterogeneity of 
the disorder in terms of its diagnostic symptoms and the current absence of a pathophysiology basis 
to diagnosis, the obtaining of such increased understanding is bound to be extremely challenging. 
The heritability-liability estimate for depression, based on analysis of its relative concordance in 
monozygotic versus dizygotic twins, is 30-40%, with the remaining liability (60-70%) attributable to 
individual-specific environmental factors (Sullivan et al., 2000). Accordingly, aetiological models of 
depression emphasise the importance of both the genetic and the environmental contributions and 
indeed their interaction (Duncan and Keller, 2011). Gene-environment interaction (GxE) is itself 
complex and potentially includes additive, synergistic and protective effects. Furthermore, additional 
factors including the potential for GxE effects to be developmental-stage specific (Ansorge et al., 
2007) and for their mediation by epigenetic mechanisms rather than specific DNA nucleotide 
sequences (Petronis, 2010), add to the complexity of understanding depression aetiology (see 
section 2.6). One important consequence of these various levels of complexity has been the 
recognition that it will be essential to study aetiology in terms of specific markers or dimensions of 
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depression in addition to – or quite possibly even instead of - its heterogeneous entirety. This will 
include analysis of the inter-relationships between genes and depression-relevant endophenotypes 
and between GxE and depression-relevant state markers or intermediate phenotypes, with both of 
these approaches conducted at the level of cells, neurocircuits and behaviour. 
 The present review aims to present the case that progress can be made in understanding the 
genetics of depression by focussing on those genes for which there is robust (e.g. with independent 
replication) evidence for association with depression and then studying these same genes in valid 
mouse models of depression. The review sets the scene by summarizing the current status of the 
evidence for the genetics (i.e. genetic aetiology) of depression1
 
. This evidence is presented under the 
methodological sub-headings: genome-wide association studies, candidate gene case-control studies, 
gene-environment interaction studies, GxE - state marker and G - endophenotype studies, post 
mortem gene expression studies, and mediating mechanisms. For each gene for which one or more 
of these methods has provided robust evidence for an association with depression (specifically, with 
replication in the case of association studies), the current evidence for the impact of this gene in 
mouse models, is presented. The mouse evidence is presented in sections corresponding to those 
used to present the human data, with descriptions of the effects of manipulation of the relevant 
genes on depression-relevant behaviour and of the effects of depression-relevant environmental 
events on the brain expression of the relevant genes.  Figure 1 illustrates the approach used. This 
review of the current evidence is followed by a critical assessment of the experimental designs used 
and the evidence obtained to date. The review concludes with proposals for future experimental 
designs with the aim of maximizing the potential in mouse models for increasing understanding of 
the aetio-pathology of depression and its pharmacological treatment. 
     (FIGURE 1 ABOUT HERE) 
 
2. Current status of the human evidence for the genetics of depression 
2.1. Genome-wide association studies  
Genome-wide association study (GWAS) allows for hypothesis-free, population-level identification of 
those genes in which a variant, typically a single-nucleotide polymorphism, is associated with a 
phenotype, which can range from a specific character to a complex disorder. Genome-wide 
association studies are based on a case-control design in which a large sample of patients and 
controls are compared in terms of genotyping single-nucleotide polymorphisms (SNPs) across the 
entire human genome. The frequency of each polymorphism of each SNP is compared for differences 
                                                          
1 As stated at the outset, here we are deploying the generic term depression to refer to major depressive 
disorder and are not addressing bipolar disorder. 
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between the patient and control cohorts. Given the enormous number of pair-wise statistical tests 
that this requires, the threshold of statistical significance is stringent and the required sample size 
correspondingly very large (Manolio, 2010). Of the eight GWAS studies for depression published to-
date, seven have reported no loci and one has reported one locus of possible genome-wide statistical 
significance, namely the neuronal amino acid transporter gene SLC6A15 (Kohli et al., 2011) (Table 1). 
A mega-analysis of these studies included more than 9000 subjects each for the depression and 
control groups, and 1.2 million single-nucleotide polymorphisms (SNPs): no locus of genome-wide 
statistical significance was identified (Sullivan and Consortium, 2012). Given the genetic architecture 
hypothesised for depression (e.g. a large number of contributing loci, small effect sizes, GxG 
interaction effects and GxE interaction effects), the heterogeneity of its symptoms and state markers, 
and its high prevalence, even such a mega-analysis is proposed to be underpowered to detect “genes 
for depression” at the genome-wide level (Sullivan and Consortium, 2012). 
 
2.2. Candidate gene case-control association studies 
A considerable number of case-control association studies of specific candidate genes for depression 
have been conducted, stimulated by specific hypotheses for aetio-pathogenesis. Findings have been 
largely negative and inconsistent. Given that insufficient sample size/statistical power could be a 
limiting factor, meta-analysis of such studies has been carried out. An analysis of all depression case-
control genetic association studies published up to 2007 revealed 22 polymorphisms that had been 
examined in at least three independent studies, and these were chosen for meta-analysis. This 
identified significant association of a polymorphism with depression for six genes: dopamine 
receptor 4 (DRD4), apolipoprotein (APOE), guanine nucleotide-binding protein subunit beta-3 
(GNB3), methylenetetrahydrofolate reductase (MTHFR), dopamine transporter (SLC6A3), and 
serotonin transporter (SLC6A4) (Lopez-Leon et al., 2008) (Table 1). For at least one of these genes, 
namely MTHFR, a subsequent well-powered case-control study did not replicate the association 
(Gaysina et al., 2008).  
 Another approach has been to analyse polymorphism associations reported in more than one 
case-control study in a relatively large sample collected for GWAS; the focus on specific candidates 
allows for an increase in power in the statistical model used (Bosker et al., 2011). Of the 57 genes/92 
SNP candidates analysed, three SNPs associated with depression were identified, one in the 
chromosome 5 open reading frame 20 gene (C5orf20) (also referred to as dendritic cell nuclear 
protein-1 (DCNP1)), one in the neuropeptide Y gene (NPY), and one in the tumor necrosis factor gene 
(TNF). In addition, the norepinephrine transporter gene (NET) exhibited significantly more SNPs with 
an association with depression than would be expected by chance (Bosker et al., 2011) (Table 1). It is 
striking that C5orf20, NPY and TNF each has an important function in the immune system: C5orf20 is 
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important in antigen presentation, NPY is involved in T helper type 1 cell differentiation, and TNF is a 
pro-inflammatory cytokine. Limitations of this study were that one-third of the candidate SNPs were 
not present on the microarray chip, and certain length polymorphisms associated with depression, 
including the 22-23-bp insertion/deletion polymorphism in the promoter region of SLC6A4, were not 
detectable (Bosker et al., 2011; Lopez-Leon et al., 2008). 
 The final gene-depression association to be presented in this section was reported in a 
genome-wide linkage analysis conducted in a family-based depression study (Schol-Gelok et al., 
2010). A linkage to depression was determined for four chromosomal regions. In one of these, 
11q25, a follow-up GWAS study combined with a high-power statistical model identified a significant 
association of the opioid binding protein/cell adhesion molecule-like (OPCML) gene with depression 
(Schol-Gelok et al., 2010) (Table 1). 
 In summary, as for GWAS, the candidate gene case-control (CGCC) approach has identified 
only a small number of genes in which one polymorphism exhibits differential association with 
depression. The approach of Lopez-Leon and colleagues (Lopez-Leon et al., 2008), of considering only 
those polymorphisms in which evidence for association had been replicated is to be commended 
and, indeed, the criterion of replication is advocated for all approaches to identifying gene-
depression association (e.g. (Duncan and Keller, 2011)). However, it should be noted that the last 
replication meta-analysis was conducted with studies published up to 2007 (Lopez-Leon et al., 2008) 
and it is therefore possible that replication of initial CGCC association findings has been obtained for 
some additional genes in the mean time. 
     (TABLE 1 ABOUT HERE) 
 
2.3. Gene-environment interaction studies 
According to the GxE aetiology model (e.g. (Caspi and Moffitt, 2006)), depression is the consequence 
of bi-directional interaction between specific genetic traits in the brain or body and environmental 
events (e.g. stressors) that induce physiological changes. Specifically, the model proposes that the 
altered genomic-proteomic expression resulting from GxE is an aetiological trigger for depression. 
The GxE model acknowledges the complexity of the aetio-pathology of depression. The most 
informative interaction would be that which involves an allele of a gene that is associated with a 
marked (synergistic) increase in the prevalence of depression in individuals that have experienced 
environmental stress, whilst other alleles of the gene are without effect (i.e. they exert a relative 
resilience effect). 
 The candidate gene (cG) for which GxE (or cGxE) provides the most convincing evidence to-
date for an aetiological association with depression is SLC6A4 (serotonin transporter), which is also 
one of the small number of genes that has been linked with depression using candidate gene case-
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control association (i.e. G main-effect; section 2.2, Table 1). In a longitudinal prospective study, the 
percentage of probands diagnosed for depression at age 25 years depended on genetic status in 
terms of the 22-23-bp insertion/deletion (“long”, L/“short”, S) polymorphism in the promoter region 
of SLC6A4 in interaction with the number of stressful life events (SLE) experienced in 
childhood/young adulthood. Those carriers of the S allele who had experienced ≥ 3 SLEs were 2-3 
times (35 % prevalence) more likely to be depressed than the probands in each of the other GxE 
groups, among which the likelihood of depression was equable (10-15 % prevalence) (Caspi et al., 
2003). A meta-analysis of this and the many subsequent studies of this GxE interaction provided 
positive evidence when the SLEs were experienced in childhood (Karg et al., 2011), although the 
methodology used for this meta-analysis has received some criticism (Duncan and Keller, 2011). 
 Additional examples of candidate genes for which evidence for GxE association with 
depression have been reported include the FK506 binding protein 51 gene (FKBP5) and the 
corticotropin-releasing hormone receptor type 1 gene (CRHR1) (Table 1). These genes encode, 
respectively, FKBP5, a member of the protein complex that modulates function of the glucocorticoid 
receptor, and CRHR1, the major receptor mediating the neuroendocrine and neurotransmitter stress 
responses caused by CRH. These stress-relevant genes were selected as candidates for GxE 
association with depression based on the potential for specific polymorphisms to increase reactivity 
to environmental stress. For FKBP5, young-adult subjects who were homozygous for minor SNP 
alleles and who had experienced traumatic events were at increased risk of depression 
(Zimmermann et al., 2011). For CRHR1, adult depression was associated with interaction between 
SNP alleles and childhood exposure to parental abuse (Bradley et al., 2008), with high cortisol titres 
also being associated with the same GxE interaction (Tyrka et al., 2009).   
 As is the case for G main effects, it is also likely that GxE studies have been underpowered to-
date. There are several reasons for this, including the vicious circle of the low probability of selecting 
the correct genes and environmental factors for analysis, because of the current poor understanding 
of depression aetiology (Duncan and Keller, 2011). Genome-wide GxE association studies would be a 
valuable approach to overcome this current deficit. Another reason is that depression aetiology is 
likely to be polygenic and poly-environmental. The GxE model can be built-up to, in principle, include 
a large number of genes and several age-specific environmental stressors i.e. the GnxEn model. Given 
the heterogeneity of the diagnostic entity of depression, then it is probably unrealistic to expect to 
identify the GnxEn terms that explain its aetiology. Focussing on specific depression symptoms, or 
associated neural or psychological state markers/intermediate phenotypes, and ensuring that the 
study sample is homogeneous for the symptom/state marker under investigation, is predicted to be 
more conducive to the discovery of GnxEn models that account for a substantial proportion of the 
prevalence of those symptoms/state markers. Even further focus, to the level of genetic traits or 
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endophenotypes that predict symptoms/state markers, is the realistic level for identification of main 
effects of specific alleles (Hasler and Northoff, 2011), as discussed next.  
 
2.4. GxE - state marker and G - endophenotype association studies 
Referring to the association of GxE with specific symptoms/state markers of depression, it is again 
the serotonin transporter gene - SLC6A4 - that has received most attention. Healthy probands 
homozygous for the S allele with a history of stressful life events (high SLE) exhibited increased 
bilateral amygdala activation in response to fearful faces (Alexander et al., 2012), and increased 
cortisol response to a laboratory social stressor (Alexander et al., 2009), relative to each of the other 
GxE groups. Furthermore, the S 5-HTTLPR x high SLE probands were characterized by an increased 
functional coupling between the right amygdala and the hypothalamus, which would be consistent 
with a link between neural and neuroendocrine hyper-reactivity (Alexander et al., 2012). In another 
study, healthy probands were screened for negativity bias, i.e. the extent to which the person 
focuses emotionally and cognitively on negative life events. Within the group displaying high 
negativity bias, probands carrying the S allele who experienced early life stress exhibited particularly 
high negativity bias, associated with increased activation (fMRI BOLD) in the vmPFC (Brodmann’s 
area (BA)11) during exposure to fearful stimuli (Williams et al., 2009). Focussing on specific markers 
in this way also facilitates advancing beyond black-box aetiology to pathophysiology. For example, 
recently it has been proposed that S 5-HTTLPR x high SLE leads to a level of activity in the circuitry 
involving amygdala, anterior cingulate cortex and dorsal raphe nucleus that is commensurate with 
depression (Disner et al., 2011; Jasinska et al., 2012). In line with the evidence that the S allele is a 
risk genotype in interaction with SLE in early life particularly, the interaction between the 5-HTTLPR 
polymorphism and early childhood adversities was studied in terms of negative feedback sensitivity 
to reward omission using the probabilistic reversal learning test (see Section 3.2) (Owens et al., 
2012). There was a significant GxE interaction for negative feedback sensitivity (NFS) due to the 
relatively low and high NFS in S carriers without and with early life SLE, respectively, relative to the L-
carrier groups (Owens et al., 2012).   
 Also at the level of endophenotype, i.e. without taking SLEs into account, the the 5-HTTLPR 
polymorphism has been the major focus. The association of the S and L alleles with amygdala 
activation in response to aversive stimuli e.g. photographs of fearful faces, as assessed using 
functional imaging, has been investigated in a number of studies. The first such study reported that 
healthy S allele carriers exhibit relatively increased amygdala activation by aversive stimuli (Hariri et 
al., 2002). A meta-analysis of 5-HTTLPR genotype and amygdala activation included both healthy 
probands and patients, and reported that overall the S allele is associated with a small increase in 
amygdala activation by aversive stimuli relative to the L allele (Murphy et al., 2012). In the negativity 
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bias study (Williams et al., 2009), the S allele was associated with increased activation in the 
midbrain, dmPFC (BA6) and ACC (BA32) in response to fearful faces (Williams et al., 2009). A meta-
analysis of association between 5-HTTLPR genotype and cortisol reactivity to acute psychosocial 
stress reported increased reactivity in carriers of the S allele (Miller et al., 2012). It has been 
hypothesized that the life-span phenotypes of S 5-HTTLPR are a consequence of its effects on the 5-
HT system during early life development of corticolimbic circuitry, and that S allele carriers will 
therefore be sensitive to GxE during early life development, with long-term consequences (Caspi et 
al., 2010). 
 
2.5. Post mortem gene expression studies 
In terms of using a life span approach to research into the genetics of depression, GxE - particularly 
early life E - aetiology studies are at one extreme, and post mortem studies at the other. Post mortem 
quantification of gene expression in target brain regions allows for identification of consistent down- 
or up-regulation of gene expression relative to an appropriate control group. As for polymorphism-
depression association studies, either a GWAS or candidate gene approach is used. Indeed, in 
principle (although to date rarely in practise), quantification of gene expression can be combined 
with genotyping in order to assess whether changes in gene expression associated with depression 
are polymorphism-specific. The major findings of these studies are summarised below and in Table 2. 
In post mortem gene expression studies, the cause of death for probands in the depressed cohort are 
suicide, natural causes and accidental, with the latter two also being the causes of death in the 
control cohort. Given that suicide is most common in people who have experienced repeated 
depression episodes and are treatment-resistant, gene expression studies typically include subjects 
with this severe form of depression. The brain regions of interest are based on current understanding 
of the neurocircuitry of depression (e.g. (Disner et al., 2011)), and include temporal cortex, frontal 
cortex, subgenual anterior cingulate cortex, and amygdala (Table 2).  
     (TABLE 2 ABOUT HERE) 
 
 For temporal cortex, a GWAS study (Aston et al., 2005) identified significant expression 
changes for families of genes involved in neurodevelopment, signal transduction and cell 
communication. A number of genes related to oligodendrocyte function were decreased in their 
expression in depression, including genes encoding structural components of myelin and genes 
encoding enzymes for synthesis of myelin constituents (Table 2). Decreases in multiple myelination-
related genes could contribute to the reduction in white matter observed in depression, which is 
proposed to cause deficient axonal function and synaptic degeneration (Aston et al., 2005). 
 For frontal cortex, a study of dorsolateral prefrontal cortex (dlPFC, Brodmann’s area (BA) 9)) 
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and ventral PFC (BA47) did not identify any significant gene expression-depression associations, 
neither by GWAS nor by a candidate-gene approach based on specific aetio-pathology hypotheses 
(e.g. 5-HT receptors) (Sibille et al., 2004). In a GWAS study of primarily vPFC (BA44, 45, 46, 47), genes 
exhibiting altered expression in depression relative to controls were grouped according to their 
function (ontology). Genes involved in cell cycle control and cell division exhibited altered expression 
in BA44 in depression, as did genes involved in transcription in BA44 and BA47, genes involved in 
myelination in BA46, and genes for GABA and glutamate receptors in BA46; however, the direction of 
change in expression for each individual gene was unspecified (Klempan et al., 2009) (Table 2). A 
study of dorsal anterior cingulate cortex (dACC, BA24) and dlPFC (BA9) also identified altered 
expression of genes involved in GABA and glutamate neurotransmission in depression (Choudary et 
al., 2005). Another study of BA9 identified dysregulation of the genes stresscopin (UCN3), Forkhead 
box 3 (FOXD3) and cannabinoid receptor 2 (CNR2), in depression (Kang et al., 2011) (Table 2).  
 A GWAS study of anterior PFC (BA10) identified up-regulation of genes involved in apoptosis. 
Furthermore, analysis of genes according to functional groups provided evidence for up-regulation of 
a number of pro- and anti-inflammatory cytokine genes (Shelton et al., 2011) (Table 2). The study of 
BA9 also identified increased expression of a TNF receptor and an interferon receptor in depression 
(Kang et al., 2011). In addition to this post-mortem evidence and the identification of depression-
association of polymorphisms of immune function genes  in case-control studies (Section 2.2.; Bosker 
et al., 2011), a meta-analysis of studies of blood levels of cytokines in depression reports increased 
levels of the pro-inflammatory cytokines TNF and interleukin-6 (IL-6) (Dowlati et al., 2010). These 
various lines of evidence have contributed to the increasing interest in the pro-inflammatory 
cytokine hypothesis of depression (Dantzer et al., 2008). Both descriptive human and experimental 
animal studies demonstrate the association between psychosocial stress and increased cytokine 
levels in the periphery (human, animal) and CNS (animal) (Miller et al., 2009). Increased cytokine 
activity in humans, related to autoimmune disease, cytokine therapy or an experimental procedure, 
is associated with a number of depression symptoms including dysphoria, anhedonia, fatigue, 
decreased appetite and weight loss. In rodents, induced increases in cytokine levels lead rapidly to a 
period of sickness (fever, anorexia, hypokinesia, hypersomnia) that subsides and is followed by a 
period of depression-relevant behaviour (e.g. reduced sucrose preference, see Table 3) (Dantzer et 
al., 2008; Schiepers et al., 2005).  
 For subgenual anterior cingulate cortex (ACC, BA25) and amygdala, a study was conducted 
using a cross-species approach: Microarray was conducted in a depression versus control human 
sample and in mice exposed to chronic unpredictable stress (CUS, a composite environmental 
stressor over weeks involving different manipulations e.g. placement in another animal’s cage, 
reversal of light/dark cycle to activate stress systems) versus control handling. Genes exhibiting a 
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change in expression in the same direction in depressed humans and CUS mice were regarded as 
significantly affected (Sibille et al., 2009). For amygdala, there were reciprocal changes in gene 
expression in depressed humans and CUS mice, and according to various criteria a core set of 32 
genes, expressed in either glia or neurons, was identified. Examples of up-regulated genes were 
those encoding: potassium channel tetramerisation domain containing 12 protein (KCDT12) of the 
GABA receptor B; calcium channel, voltage-dependent, beta 2 subunit (CACNB2); and 
calcium/calmodulin-dependent protein kinase II delta (CAMK2D). Examples of down-regulated genes 
were: plasma membrane proteolipid (PLLP); myelin-associated oligodendrocyte basic protein 
(MOBP); and G protein-coupled receptor 37 (GPR37) (Sibille et al., 2009) (Table 2).   
Summarizing the findings of post mortem studies of depression-associated changes in gene 
expression in specific brain regions, there is currently evidence for prefrontal cortex, anterior 
cingulate cortex, temporal cortex and amygdala. For a number of functional classes of genes, there is 
evidence that expression levels of genes in the same functional class are changed in the same 
direction in at least two different brain regions. Examples of such functional classes with potential 
aetio-pathological importance for depression include astrocyte- and oligodendrocyte-specific genes, 
synaptic protein genes, cytokine pathway genes, GABA- signalling/function genes and glutamate-
signalling/function genes. 
 
2.6. Mediating mechanisms: from polymorphic risk to epigenetic response 
The major aim of this review is to assess the extent to which mouse models provide supportive 
causal evidence for the human descriptive evidence that depression is associated with specific gene 
polymorphisms and with (post mortem) altered levels of expression of specific genes. Nonetheless, it 
is also important to consider the mechanisms via which these inter-relationships can be mediated. 
There are three major categories of mediating mechanism: Firstly, a polymorphism in a specific gene 
can result in increased/decreased expression of its protein product, which in turn predisposes the 
individual to respond to SLEs such that depression risk is increased (cG x E). Second, an 
environmental event (e.g. SLE) results in increased/decreased levels of physiological-neurobiological 
factors that lead to increased/decreased activity of specific transcription factors and 
increased/decreased expression of specific genes, in turn leading to increased depression risk (E x 
cG). The impact of the increase/decrease in the level of a physiological-neurobiological factor might 
depend on polymorphism in relevant genes. Third, an environmental event (e.g. SLE) results in 
increased/decreased levels of physiological-neurobiological factors that lead to increased/decreased 
activity in epigenetic processes, in turn leading to increased depression risk (E x epi-cG). The 
epigenetic processes are altered methyltransferase activity and level of methylation of DNA, leading 
to decreased transcription-factor binding in promoter regions of specific genes; and de/acetylation of 
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the histone proteins that regulate chromatin density, leading to, respectively, decreased/increased 
accessibility of DNA in promoter regions of specific genes. An example for each of the three 
mechanisms via which altered gene expression can be linked to increased risk for depression is 
provided here.  
 cG x E: The SLC6A4 short variant provides a well-studied example of a polymorphism 
associated with a distinctive protein phenotype that predisposes its carriers, via cGxE, to increased 
depression prevalence. The cGxE interaction is with early life/developmental stressors (see section 
2.3.). Serotonin has important functions as a neurotransmitter and trophic factor during the 
maturation of the CNS, including modulation of neuronal division, differentiation and migration, 
growth cone elongation, synaptogenesis and dendritic pruning. It has been proposed that high levels 
of 5-HT during CNS development, as facilitated by reduced 5-HTT levels in 5-HTTLPR S carriers, will 
impact on these processes (Ansorge et al., 2007). Developmental stressors might interact with high 
basal 5-HT and/or might act a posteriori on the consequences of high basal 5-HT, to increase the 
depression risk of 5-HTTLPR S carriers.  
 E x cG: The evidence that SLEs lead to increased levels of pro-inflammatory cytokines and 
that the cytokine treatments used for certain illnesses often lead to depression, is consistent with 
environment-induced expression of pro-inflammatory cytokine genes providing an example of the 
second mechanism via which altered gene expression increases depression risk. That polymorphism 
at the TNF gene is associated with depression (Table 1) suggests that, for this cytokine, cG x E and E x 
cG mechanisms could act in unison.  
 E x epi-cG: Despite the justifiable growing interest in SLEs leading to brain region-specific 
changes in gene expression in depression via effects on epigenetic processes, to-date there is very 
limited evidence for epigenetic markers in the post-mortem depressed brain. One relevant study has 
reported that in hippocampal tissue from adult suiciders with a developmental history of abuse, 
decreased glucocortoid receptor (GR) expression co-occurred with increased DNA methylation in   
the GR promoter (McGowan et al., 2009). Nevertheless, animal studies have yielded evidence that 
genes associated with human depression do exhibit changes in expression of depression-relevant 
genes that are associated with epigenetic changes in response to environmental factors. Examples 
include: decreased hippocampal GR expression and increased GR-promotor DNA methylation in adult 
rats that experienced low levels of maternal behaviour (Weaver et al., 2004); decreased hippocampal 
BDNF expression and decreased acetylation levels on histone residues in adult mice and rats that 
experienced social defeat and exhibited depression-relevant behaviour in adulthood (Sun et al., 
2013); and increased acetylation levels on histone residues in adult mice that experienced 
environmental enrichment and improved cognition in adulthood (Fagiolini et al., 2009). Clearly, 
epigenetic factors are at the interface between environmental stimuli and long-lasting – indeed even 
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inter-generational – changes in gene expression that impact on molecular, cellular, regional and 
behavioural phenotypes (Petronis, 2010).        
 
3. Mouse models for the genetics of depression 
3.1. Genetic tools 
The study of the genetic regulation of brain function and behaviour in mice in order to increase 
understanding of the contribution of expression of specific genes to the aetio-pathogenesis of 
depression can be divided into two broad methodological strategies. These strategies are 
complementary to those used in human gene polymorphism-depression association studies and 
depression-gene expression studies, respectively. Firstly, the effects in mice of manipulation of genes 
for which specific polymorphisms have been demonstrated to be differentially associated with 
depression in human, can be studied i.e. the reverse genetics approach. One major method here is 
homologous recombination of a gene with non-transcriptional DNA to generate a null mutant 
(knockout) or heterozygous mutant (partial knockout) mouse (Jackson and Abbott, 2000).  For a 
human gene in which a polymorphism leading to reduced biological activity of the encoded protein is 
associated with depression, mice that are partial knockout for the homologous gene could provide an 
appropriate genetic model in comparison with the wildtype. Another major reverse genetic method 
is gene knock-in: With transgenic knock-in a specific additional allele and its regulatory regions are 
incorporated into the genome to generate “over-expressing” mice. With targeted knock-in, an allele 
already present in the mouse is targeted with a specific mutation that impacts on its transcription or 
translation (Jackson and Abbott, 2000). For a human gene in which a polymorphism leading to 
increased biological activity of the encoded protein is associated with depression, mice that over-
express the protein (transgenic knock-in) or  express the protein in its depression-risk amino acid 
sequence (targeted knock-in) could provide an appropriate genetic model in comparison with the 
wildtype (Jackson and Abbott, 2000). Such heterozygous-knockout and knock-in mouse models and 
their wildtype controls can be studied in depression-relevant readouts in order to investigate genetic 
aetiology of endophenotypes and their mediating mechanisms. Furthermore, such mice can be 
exposed to environmental-stress manipulations followed by study in depression-relevant readouts in 
order to investigate GxE interaction aetiology of state markers and their mediating mechanisms. The 
second broad methodological strategy is to study the expression of genes in specific brain regions in 
mice modified genetically and demonstrated to exhibit depression-relevant endophenotypes, or in 
mice (possibly modified genetically) exposed to environmental stress and demonstrated to exhibit 
depression-relevant state markers, relative to their respective control groups i.e. the forward 
genetics approach (Causton et al., 2003). 
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 Some of the major evidence obtained to-date from mouse models aimed at increased 
understanding of the genetics of depression is summarised below. The evidence is presented 
according to the two methodological strategies of reverse (section 3.3.) and forward genetics 
(section 3.4.) used to obtain it.    
 
3.2. Behavioural readouts  
As noted in the Introduction: depression is classified as a heterogeneous group of mental and 
physical symptoms; the neuropsychological processes and their pathological states that underlie the 
mental symptoms need to be characterized thoroughly; specific depression-relevant pathological 
states will demonstrate a much closer causal relationship with the expression levels of depression-
relevant genes than will the diagnostic entity of depression. Major examples of psychopathological 
states associated with depression are given in Table 3, together with the symptom which each state 
underlies/is associated with. Another major advantage of the focus on specific neuropsychological 
processes is that it renders the study of depression considerably more amenable to animal model 
studies. In this regard, also given in Table 3 are some major examples of the behavioural tests that 
have been established to measure depression-relevant neuropsychological processes in humans, 
together with the analogous tests that have been developed in mice. 
     (TABLE 3 ABOUT HERE) 
 To recall, the major rationale for this review is to take those genes for which there is 
descriptive evidence for an association with depression and then to review the experimental (causal) 
evidence obtained in mice for the involvement of these genes in the regulation of depression-
relevant behaviour. Accordingly, it would of course be optimal if the mouse studies conducted into 
behavioural effects of the genes in question had focused on translational depression-relevant 
behavioural tests, as given in Table 3. In reality, the behavioural effects of manipulation of the 
identified depression-associated genes have been studied to-date in terms of sucrose preference 
(Willner, 1997), fear conditioned freezing (Stiedl et al., 1999), the specific learned helplessness effect 
(or unconditioned stimulus pre-exposure effect) (Pryce et al., 2012), and the probabilistic reversal 
learning test (Ineichen et al., 2012). In the sucrose preference test, mice are presented with two 
bottles, one filled with sucrose (or saccharin) solution and one with water and the proportion of 
consumption of the sweet-tasting solution relative to total consumption is measured across several 
hours/days. The proportion of consumption of the sweet-tasting solution is typically 80-90% and 
decreases are therefore detectable and interpreted as reduced reward sensitivity. In fear 
conditioned freezing, mice are exposed to a specific context and a specific discrete stimulus (e.g. 
tone) that predicts an aversive unconditioned stimulus, typically inescapable electro-shock. During 
this exposure, mice develop freezing behaviour and they also express this fear behaviour on 
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subsequent days, when re-exposed to the context or the discrete stimulus. Freezing in this test 
provides a measure of reactivity to aversive stimuli and is sensitive to the mouse’s reactivity to the 
aversive unconditioned stimulus as well as its reactivity in terms of learning and memory about the 
context and discrete stimulus that predict the unconditioned stimulus. In the specific learned 
helplessness effect test, two groups of mice are pre-exposed to the same number, duration and 
intensity of aversive unconditioned stimuli, typically electro-shocks, and in one group these stimuli 
are escapable and in the other group they are inescapable. The mice pre-exposed to inescapable 
aversive stimuli exhibit a deficit in escape behaviour when, at the test phase, they are exposed to 
escapable e-shocks. In the unconditioned stimulus pre-exposure effect version, mice are pre-exposed 
to either inescapable or no aversive stimuli. In the probabilistic reversal learning test, mice are 
trained to exhibit operant behaviour to obtain reward and to exhibit serial spatial reversal learning. 
Super-imposed on the spatial reversal schedule, a low proportion of correct responses are punished 
in the form of non-delivery of reward. The major readout is, on the next trial, whether mice exhibit 
appropriate lose-stay or inappropriate lose-shift behaviour, with high levels of the latter indicating 
high negative feedback sensitivity. As stated in Table 3, the specific learned helplessness effect test 
and the probabilistic reversal learning test can be applied in both humans and mice and, 
furthermore, learned helplessness is increased (Pryce et al., 2011) and probabilistic reversal learning 
deficient (Taylor Tavares et al., 2008) in depression.        
 A significant number of the relevant genetic mouse model studies have been conducted with 
four additional categories of behavioural test, and these are also included in this review. The first 
additional category that has been frequently used to study the effects of depression-associated 
genes is the current-antidepressant screening tests, namely the forced swim test (FST) (Lucki et al., 
2001; Porsolt et al., 1977) and the tail suspension test (TST) (Steru et al., 1985). In both of these tests, 
motor inactivity develops across time in the test, and this increase in inactivity is antagonised by 
acute or chronic administration of reference antidepressant drugs, primarily selective serotonin 
reuptake inhibitors (Cryan et al., 2005; Lucki et al., 2001). The neuropsychological processes 
underlying both the development of inactivity and its pharmacological antagonism are unclear. 
Whilst behavioural despair resulting from uncontrollable stressor exposure is often cited as the 
mediating mechanism, this is a subjective interpretation that cannot be tested and such tests are 
deficient in the face and construct validity that are essential to conferring depression-relevance 
(Pryce and Seifritz, 2011). The justification for nonetheless including these studies is that the findings 
for effects or non-effects of depression-relevant genotypes in these tests might potentially increase 
understanding of the neuropharmacological mechanisms mediating current-antidepressant effects. 
The second additional category of behavioural test that has been used to study the effects of 
manipulation of depression-associated genes in mice is cognitive tests, represented by the delay 
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discounting test of impulsivity, the Go/No-go test of response inhibition/impulsivity (Helms et al., 
2008), and the continuous performance test of sustained attention incorporating a No-go response 
inhibition component (Young et al., 2011). The inclusion of tests of cognitive function is justified by 
cognitive deficits being common in depression, by these tests being applicable in both humans and 
mice, and by human depression being associated with deficits in these tests (Koetsier et al., 2002). 
The third additional category of behavioural test that has been frequently used to study the effects 
of manipulation of depression-associated genes in mice is the anxiety/anxiolytic screening tests, 
represented by the elevated plus maze test (Dawson and Tricklebank, 1995) and the light-dark box 
test (Crawley and Goodwin, 1980). These tests are based on the conflicting emotional-/motivational-
state hypothesis of anxiety (Gray and McNaughton, 2000), with the conflict being approach-avoid 
relative to the respective physical properties of the different areas of the apparatus in the case of 
both the elevated plus maze and light-dark box tests. The justification for including studies reporting 
on these tests here is the high prevalence of anxiety disorders in depression (see section 1) and the 
possibility that the findings for effects or non-effects of depression-relevant genotypes in these tests 
could increase understanding of the genetic aetiology of psychopathology relevant to anxiety 
disorders and depression. The fourth additional category of behavioural test that has been used 
frequently to study the effects of manipulation of depression-associated genes in mice is the general 
activity tests, represented by the open field test (Prut and Belzung, 2003). Measurement of general 
locomotion in a novel environment allows for assessment of the effect of a genetic manipulation on 
basic activity: given that other tests are activity dependent and their findings can be confounded by 
general activity effects, it is essential that basic activity is included in the behavioural phenoytping of 
the genetic model. 
 
3.3. Mouse models informed by the human evidence for polymorphisms associated with 
depression 
In this section, studies are presented that have addressed the effects of knockout or over-expression 
of genes for which it has been demonstrated, either by GWAS, CGCCS meta-analysis and/or GxE 
study, that specific polymorphisms are differentially associated with depression. The relevant genes 
and their risk polymorphisms are given in Table 1.   
 
3.3.1. Serotonin transporter (mouse nomenclature: Slc6a4, 5-HTT, SERT; protein: 5-HTT, SERT) 
Serotonin transporter (5-HTT) is synthesised by 5-HT neurons and is located on 5-HT axon terminals 
where it performs pre-synaptic reuptake of 5-HT and thereby is a major regulator of 5-HT level and 
post-synaptic receptor binding in the synaptic cleft. The serotonin transporter gene (SLC6A4) is 
associated with depression in terms of polymorphism in the copy number of a 22-23-bp repeat that 
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constitutes the 5-HTTLPR, with either 14 ((S)hort/deletion) or 16 ((L)ong/insertion) copies of the 
repeat (Haddley et al., 2008). To summarize, the S allele was associated with increased risk of 
depression in meta-analysis (Lopez-Leon et al., 2008) (Table 1). The interaction of the S allele x 
multiple SLEs - particularly early life SLEs - was associated with increased risk of depression in meta-
analysis (Karg et al., 2011). In healthy probands, the S 5-HTTLPR allele was associated with increased 
neuroticism (Lesch et al., 1996) and increased amygdala activation by fearful faces (Hariri et al., 
2002). The interaction S allele X SLE was associated with increased bilateral amygdala activation in 
response to fearful faces (Alexander et al., 2012), increased cortisol reactivity to acute psycosocial 
stress (Alexander et al., 2009; Miller et al., 2012), and increased negativity bias (Williams et al., 2009) 
(see above, section 2.3, 2.4). There is in vitro evidence that the S allele leads to reduced 5-HTT 
expression and function (Haddley et al., 2008). Human lymphoblast cell lines with different 5-HTTLPR 
genotypes were compared in terms of 5-HTT binding sites and 5-HT uptake: the S allele was 
associated with decreased 5-HTT activity in both the L/S and S/S genotypes (Lesch et al., 1996). The 
in vivo evidence is more equivocal: one SPECT study reported decreased 5-HTT binding in midbrain 
by S carriers but other SPECT studies reported no genotype effect. Also, positron emission 
tomography (PET) studies have not found any genotype differences in 5-HTT binding (Parsey et al., 
2006; Shioe et al., 2003). 
 There is no mouse orthologue of the human 5-HTTLPR. Slc6a4 KO mice have been generated 
and studied. Relative to WT, the 5-HTT KO mouse exhibited markedly increased extracellular 5-HT 
and reduced 5-HT clearance (Mathews et al., 2004; Montanez et al., 2003). Repeated testing in the 
FST led to a greater development of immobility in KO relative to WT mice (Wellman et al., 2007). KO 
mice spent less percent time on the open arms of an elevated plus maze and in the light 
compartment of a light-dark box, indicating increased anxiety, relative to WT (Holmes et al., 2003). 
Exposure to predator (cat) odour resulted in KO mice spending less percent time on the open arms of 
an elevated plus maze and in the light compartment of a light-dark box, relative to WT (Adamec et 
al., 2006). It is the HET-WT comparison that provides a mouse model for the reduced 5-HTT function 
associated with the S relative to L 5-HTTLPR genotype. 5-HTT HET mutant mice exhibited reduced 5-
HT clearance and increased extracellular 5-HT levels, but otherwise normal 5-HT transmission, 
relative to WT (Jennings et al., 2010; Mathews et al., 2004; Montanez et al., 2003). HET mice 
exhibited increased fear-conditioned freezing to the context in which they experienced repeated 
moderate electro-shocks, relative to WT (Pryce et al., 2012). HET mice exhibited reduced negative 
feedback sensitivity following reward omission in the probabilistic reversal test (Ineichen et al., 
2012), similar to human 5-HTTLPR S carriers (see section 2.4.). HET mice did not differ from WT in 
tests of anxiety (Holmes et al., 2003) including after exposure to predator odour (Adamec et al., 
2006). A number of studies have investigated for differential effects of environmental stressors on 
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HET versus WT mice i.e. GxE models. HET mice that received low levels of maternal care exhibited a 
reduced latency to immobility in the TST relative to HET mice that received high levels of maternal 
care but not relative to WT mice (Carola et al., 2008). Postnatal exposure to repeated electro-shocks 
was without effect on adult behaviour in FST, elevated plus maze, light-dark box, and open field, both 
as a main effect and in interaction with genotype (Carroll et al., 2007). In a learned helplessness 
model, HET and WT mice were pre-exposed across consecutive days to either escapable or 
inescapable electro-shocks and then all mice were tested in terms of escape behaviour. Both HET and 
WT mice pre-exposed to escapable electro-shocks exhibited escape behaviour at test; the deficit in 
escape behaviour in the mice that had experienced inescapable electro-shocks was greater in HET 
than WT mice, that is, HET resulted in increased sensitivity to an aversive uncontrollable 
environment (Pryce et al., 2012) (Table 3). Mice over-expressing 5-HTT have been generated and, 
whilst not constituting a model for any depression-relevant human genotype, can be studied to 
assess whether such over-expression leads to depression-relevant phenotypes. Only anxiety tests 
have been applied in such mice to-date, including the elevated plus maze test: 5-HTT over-expression 
led to reduced anxiety (Jennings et al., 2006; Line et al., 2011). 
 The 5-HTT HET versus WT model provides a relevant analogue for the 5-HTTLPR S versus L 
polymorphism at the genotypic level. Furthermore, there is some evidence for analogy at the level of 
behavioural phenotypes: healthy S carriers exhibit increased neuroticism and reactivity to fearful 
stimuli; HET mice exhibited increased fear conditioning and developed increased learned 
helplessness. Further 5-HTT x E mouse studies are required to increase understanding of the 
interaction between 5-HTT genotype and SLE, which appears to be specific to early life SLE, and   
human depression. 
 
3.3.2. Dopamine transporter (mouse nomenclature: Slc6a3, DAT; protein: DAT) 
Dopamine transporter (DAT) is synthesised by DA neurons and is located on DA axon terminals where 
it performs pre-synaptic reuptake of DA and thereby is a major regulator of DA level and post-
synaptic receptor binding in the synaptic cleft. The dopamine transporter gene (SLC6A3) is associated 
with depression in terms of a polymorphism in the copy number of a 40 base-pair (bp) variable 
number tandem repeat (VNTR), present in the 3' untranslated region (3’-UTR) (Lopez-Leon et al., 
2008). The majority of SLC6A3 alleles have either nine or ten 40-bp repeats in their 3’-UTR. Increased 
depression risk for carriers of the 9/10 genotype compared to the 10/10 genotype was demonstrated 
in a meta-analysis (Lopez-Leon et al., 2008) (Table 1). The evidence for the relationship between the 
3’UTR VNTR polymorphism and DAT function is currently inconsistent: in vivo single-photon emission 
computed tomography (SPECT) studies variously reported that the 9/10 genotype is associated with 
lower levels of DAT expression in the striatal putamen compared to 10/10, or that a genotype with at 
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least one 9 allele is associated with higher levels of striatal DAT, or the absence of an association 
between this genotype and DAT density/function (Haddley et al., 2008). In vitro studies of 
transfection of reporter plasmids containing one of the SLC6A3 3’-UTR VNTRs have also yielded 
conflicting results regarding transcriptional activity: depending on the cell line used, the 9 or the 10 
3’-UTR VNTR yielded higher transcription levels or there was no difference between the two VNTRs 
(Haddley et al., 2008). 
 The human SLC6A3 VNTR polymorphism is not present in the mouse Slc6a3 (DAT) gene. Mice 
that were DAT KO exhibited markedly increased extracellular DA levels and slower clearance of 
synaptic DA relative to WT; HET mice were intermediate but also with increased extracellular DA and 
slower DA clearance relative to WT (Gainetdinov et al., 1998; Jones et al., 1998). The DA phenotypes 
of KO and HET mice co-occurred with down-regulation of both pre-and post-synaptic DA receptors 
(Haenisch and Bönisch, 2011). Behaviourally, KO mice exhibited increased locomotor activity relative 
to WT (Giros and Jaber, 1996; Pogorelov et al., 2005). In a separate study (Perona et al., 2008), KO 
mice again exhibited hyper-locomotion relative to WT and relative to HET also. Furthermore, KO 
mice exhibited decreased immobility in the forced swim test (FST) and the tail-suspension test (TST) 
compared to WT; these phenotypes could reflect the hyper-locomotion phenotype. These DAT KO 
mice also exhibited increased sucrose preference relative to WT and HET. DAT HET mice also 
exhibited decreased immobility in the TST relative to WT and, in contrast to KO, this did not co-occur 
with hyper-locomotion. There was no difference between HET and WT in the sucrose preference test 
(Perona et al., 2008). In an open field, DAT HET mice spent more time in the centre than did WT 
(Pogorelov et al., 2005). C57BL/6 mice that had been reared in an enriched environment exhibited 
reduced DAT binding potential and reduced DAT expression per DA neuron, throughout the striatum 
(Bezard et al., 2003). However, to our knowledge, there has been no study of effects of 
environmental manipulations in DAT KO or HET mice relative to WT (i.e. GxE study). Mice over-
expressing DAT did not differ from WT in their initial (exploratory) locomotor activity when first 
exposed to a locomotor activity test, but after repeated exposures the DAT OE mice exhibited a more 
rapid decrease in activity, reflecting faster habituation to the test environment relative to WT mice 
(Donovan et al., 1999). Dopamine transporter knockdown (DAT KD) mice have also been generated 
that express 10% of WT DAT levels and have chronically increased extracellular DA in the striatum 
(Cagniard et al., 2006). These mice exhibit increased operant responding for sucrose on a progressive 
ratio schedule relative to WT, thereby demonstrating that DAT activity is an important regulator of 
reward incentive motivation.  
 Full knockout and almost complete knockdown of DAT constitute extreme situations that are 
unlikely to be of direct relevance to the role of DAT in mediating human depression risk, but are 
valuable in demonstrating the fundamental importance of DAT to psychological processes, such as 
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reward processing, that are of direct relevance to depression. Meaningful interpretation of the above 
behavioural phenotypes of DAT KO, HET and KD mice relative to WT in terms of their relevance to the 
role of DAT in human depression will first require elucidation of the relationship between 9/10 VNTR 
SLC6A3 genotype and DAT/DA phenotype. Extrapolating from the mouse evidence, it is to be 
expected that this risk genotype encodes increased mesocorticolimbic DAT activity and decreased 
sensitivity to reward. 
    
3.3.3. Dopamine receptor 4 (mouse nomenclature: Drd4; protein: D4) 
The dopamine receptor 4 (D4) belongs to the G protein-coupled receptor family and is expressed in 
the brain, at particularly high levels in prefrontal cortex and nucleus accumbens, regions central to 
emotional processing and depression (Murray et al., 2011). One function of D4 is inhibition of 
adenylyl cyclase and reduced conversion of adenosine triphosphate (ATP) to the secondary 
messenger cyclic adenosine monophosphate (cAMP) (Lopez-Leon et al., 2005). In a case-control 
candidate gene meta-analysis, the dopamine receptor gene 4 (DRD4) was associated with depression 
in terms of a polymorphism in the copy number of a 48 base-pair (bp) VNTR present in exon 3. It is 
the 2 repeats genotype that has been associated with increased depression risk (Lopez-Leon et al., 
2005) (Table 1). There is currently no definitive understanding of a relationship between this DRD4 
polymorphism and D4 function. Effects on dopamine binding or G-protein activation have been 
proposed; for example, the third cytoplasmic loop of D4, which contains the sequence encoded by 
the VNTR, can act as a SH3 binding domain and the VNTR may determine its dopamine binding 
capacity (Oak et al., 2000).  
 Mice have been generated that are null mutant for Drd4 (Falzone et al., 2002). In an elevated 
plus maze test, Drd4 KO mice exhibited fewer open arm entries and spent less per cent time on the 
open arms than WT, a difference that could not be attributed to altered general locomotor activity. 
In a light-dark box test, Drd4 KO mice displayed an increased latency to first enter and spent less time 
in the lit compartment, relative to WT. There was no difference between Drd4 KO and WT mice in 
terms of fearful freezing during conditioning or subsequent exposure to tone CS or context (Falzone 
et al., 2002). In one study reporting on tests of cognitive function, namely the delay discounting test 
and the Go/No-go test, there were no effects of Drd4 KO on behaviour relative to WT (Helms et al., 
2008). In another study, HET mice exhibited response disinhibition on a No-go test built into a 
continuous performance test, relative to WT (Young et al., 2011), which is of relevance given that 
depressed probands were also reported to exhibit response disinhibition in a continuous 
performance test (Koetsier et al., 2002). In a rotarod motor coordination test, Drd4 KO mice 
displayed reduced spontaneous locomotor activity but fewer falls and remained longer on the 
rotating rod compared to WT. These KO mice exhibited increased dopamine synthesis and turnover 
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compared to WT, indicated by higher DOPAC and L-DOPA titres in the dorsal striatum-caudate 
putamen, suggesting that one D4 function is as an inhibitory autoreceptor (Rubenstein et al., 1997). 
 Therefore, constitutional absence of Drd4 led to adult mice that exhibit increased anxiety in 
novel environment tests; there was no effect on fear conditioning. Definitive understanding of the 
relationship between the DRD4 polymorphism and D4 function will be necessary before depression-
relevant mouse genetic models of altered Drd4 function can be produced. 
 
3.3.4. Apolipoprotein E (mouse nomenclature: Apoe; protein: ApoE) 
Apolipoprotein E (ApoE) is synthesised widely in the periphery and the CNS and is essential for 
catabolism of triglyceride-rich lipoprotein constituents. The human apolipoprotein E gene (APOE) is 
polymorphic in terms of exon SNPs leading to three alleles, APOE-ε2, -ε3 and -ε4, which encode 
different amino acids at two different positions of the ApoE protein. Allele -ε3 is regarded as the 
neutral genotype. Allele -ε4 is the largest known genetic risk factor for late-onset sporadic 
Alzheimer’s disease. Allele -ε2 is associated with both increased and decreased risk for 
atherosclerosis and with increased risk for hyperlipoproteinemia (Mahley and Rall Jr, 2000). In meta-
analysis, the -ε2 allele has also been demonstrated to be associated with a lower risk for depression 
compared to the ε3 allele (Lopez-Leon et al., 2008) (Table 1). There is growing evidence for the 
interaction of ApoE with immunological processes, including macrophage and T-cell functioning 
(Zhang et al., 2010a).   
 Transgenic female mice expressing human APOE-ε2, -ε3 or -ε4 have been generated (Siegel 
et al., 2012). When compared on the elevated plus maze, the APOE-ε2 mice spent less time on the 
open arms than did APOE-ε3 mice, suggesting that APOE-ε2 was anxiogenic. In the same study, there 
was a trend to increased ApoE levels in the amygdala, hippocampus and cortex in APOE-ε2 relative to 
APOE-ε3 mice (Siegel et al., 2012). Mice knockout for Apoe exhibited a phenotype of spontaneous 
atherosclerosis. When such mice were exposed to chronic unpredictable stress (CUS) (see below, 
section 3.4), atherosclerosis was further increased (Zhang et al., 2010b). Furthermore, a number of 
blood pro-inflammatory biomarkers were also increased, including C-reactive protein and IL-6. 
Therefore, the GxE interaction of Apoe KO x CUS leads to high levels of atherosclerosis associated 
with a marked pro-inflammatory response (Zhang et al., 2010b). Extrapolating the mouse findings to 
the protective association of APOE-ε2 with depression, one possibility is that this genotype leads to 
relatively high ApoE levels that are protective against psychosocial stress; given that psychosocial 
stress stimulates immune-inflammatory activation (Miller et al., 2009), a reduced psycho-immune 
response could reduce the risk of  depression. To our knowledge, no relevant behavioural studies of 
this GxE have been conducted to-date. 
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3.3.5. Guanine nucleotide-binding protein, beta polypeptide 3 (mouse nomenclature: Gnb3; protein: 
GNB3) 
The guanine nucleotide-binding proteins (G proteins) mediate signals between receptors and effector 
proteins, including the G protein-coupled receptors of several neurotransmitters in the CNS. G 
proteins are composed of α, β and γ subunits and the GNB3 gene codes for a β subunit. A SNP 
(C825T) in GNB3 was associated with depression in a meta-analysis (Lopez-Leon et al., 2008). The T 
allele is the risk factor (Table 1). Carriers of this allele also had an increased risk of hypertension and 
obesity, both of which are co-morbid for depression. The T allele is associated with alternative 
splicing of the gene and the formation of a truncated but functionally active β3 subunit which is 
referred to as Gβ3s. Expression of the splice variant results in an enhanced G protein activation on 
stimulation of G protein-coupled receptors (Siffert, 2001). To our knowledge, to-date there has been 
no study of mice with engineered changes in Gnb3 expression in terms of depression-relevant 
neurobiology or behaviour. 
 
3.3.6. Methylenetetrahydrofolate reductase (mouse nomenclature: Mthfr; protein: NAD(P)H) 
The MTHFR gene encodes the enzyme methylenetetrahydrofolate reductase (NAD(P)H). NAD(P)H is 
important for a chemical reaction also supported by forms of the B-vitamin folate (folic acid, vitamin 
B9). Specifically, NAD(P)H converts 5,10-MTHF to 5-MTHF, the folate required for the multi-step 
process that converts homocysteine to methionine, an amino acid that is essential in neural tube 
development, for example. A common SNP in MTHFR is C677T, which results in an amino acid 
change. The TT genotype results in reduced NAD(P)H activity and elevated homocysteine levels in 
blood. It is the TT genotype that is associated with depression in case-control candidate gene meta-
analysis (Lopez-Leon et al., 2008) (Table 1). 
 Mthfr null mutant mouse models have been generated; the heterozygous mutant (HET) 
would be expected to exhibit reduced NAD(P)H activity and therefore to provide an analogue of the 
depression-risk SNP of MTHFR. KO, HET and WT mice were studied in various behavioural tests. 
Mthfr KO mice exhibited increased activity in an open field relative to WT and HET, and spent 
increased time in the open arms of an elevated plus maze. Using an object recognition test, KO mice 
exhibited both medium- and long-term object memory impairment compared to WT and HET mice. 
These behavioural changes were associated with decreased total brain weight and hippocampal 
volume relative to WT and HET mice. There were no behavioural or brain differences between HET 
and WT mice (Jadavji et al., 2012). In a separate study, which compared HET and WT genotypes, HET 
male, but not female, mice exhibited increased open-field activity relative to WT (Levav-Rabkin et al., 
2011).  
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 Therefore, constitutional absence of Mthfr led to adult mice that exhibit increased activity 
and possibly even decreased anxiety in a novel environment test. Mthfr HET mice exhibit increased 
activity but no change in anxiety. Depression-relevant tests are still to be assessed in this mouse 
model, but it is noteworthy that there is no anxiety phenotype, at least in the absence of 
environmental manipulation, suggesting that the mouse does not provide a model for the study of 
variation in human MTHFR expression and function.  
 
3.3.7. Neuron-specific neutral amino acid transporter (mouse nomenclature: Slc6a15; protein: 
SLC6A15) 
Neuronal amino acid transport by SLC6A15 has been proposed to be important in neuronal 
metabolism by functioning as a provider of substrates for glutamate synthesis (Bröer et al., 2006). 
SLC6A15, the gene encoding neuron-specific neutral amino acid transporter, was associated with 
depression in a GWAS (Kohli et al., 2011). The study identified a SNP occurring in the vicinity of 
SLC6A15 and the AA genotype of the SNP was associated with both increased risk of depression 
relative to AG + GG and with reduced expression of SLC6A15 in the hippocampus (Kohli et al., 2011) 
(Table 1). Expression of SLC6A15 was also reduced in lymphoblastoid cell lines and peripheral blood 
monocytes derived from carriers of the depression-risk genotype relative to the other genotypes. 
These findings indicate that the SNP is affecting SLC6A15 expression, via long-range regulatory 
mechanisms (Kohli et al., 2011). In the GWAS study that identified the SLC6A15-depression 
association, it was also reported that depressives exhibited reduced hippocampal volume relative to 
control probands and that this reduction was more pronounced in depressives with the AA risk 
genotype (Kohli et al., 2011). In a separate study, depressives carrying the risk genotype 
demonstrated increased plasma ACTH and cortisol activity relative to AG/GG carriers (Schuhmacher 
et al., 2012).  
 To the best of our knowledge there have been no studies conducted with mice genetically-
engineered for slc6a15. Mice that had been subjected to chronic social stress during adolescence 
exhibited decreased hippocampal expression of slc6a15 relative to control mice (Kohli et al., 2011). 
Integrating the human and mouse findings, there is preliminary evidence indicating that low levels of 
SLC6A15 in the hippocampus (and possibly other CNS regions), caused by genotype or stress or their 
interaction, could increase susceptibility to depression-relevant CNS function. Given that SLC6A15 
could be a limiting factor in glutamate synthesis, there could be a functional connection between 
SLC6A15 polymorphism and the recent interest in the glutamate NMDA receptor-antagonist, 
ketamine, as an antidepressant (aan het Rot et al., 2012).  
 
3.3.8. Chromosome 5 open reading frame 20 (mouse nomenclature: C5orf20; protein: DCNP1)  
25 
 
The C5orf20 gene encodes dendritic cell nuclear protein-1, which is expressed in the dendritic cells - 
one type of the various antigen-presenting cells that activate T cells and B cells in the immune system 
- of the CNS and skeletal muscle. A T-A SNP was identified in C5orf20, and a T at this locus codes for 
premature termination of DCNP1 translation leading to a shorter protein. Carriers of the TT genotype 
are at increased risk of depression relative to A/T + A/A, according to a study that used a combined 
GWAS and candidate gene case-control approach (Bosker et al., 2011) (Table 1). To the best of our 
knowledge there have been no studies conducted with mice genetically-engineered for C5orf20 to-
date. 
 
3.3.9. Tumor necrosis factor (mouse nomenclature: Tnf; protein: TNF) 
The TNF gene encodes tumor necrosis factor, the pro-inflammatory cytokine that is synthesized by 
macrophages and T cells in the periphery and by neurons and glia in the CNS (Miller et al., 2009). A C-
A SNP has been identified in TNF that was associated with depression (Bosker et al., 2011) (Table 1). 
The publication does not state whether C or A is the risk nucleotide and any association between the 
SNP and TNF expression and/or TNF function also remains to be described. A meta-analysis of blood 
levels of cytokines in depressed relative to control probands reported that TNF levels were increased 
in depression (Dowlati et al., 2010). 
 Mice that are null mutant for Tnf have been generated, as have mice null mutant for the TNF 
receptors, TNF receptor superfamily member 1a (Tnfrsf1a (Tnfr1)) and TNF receptor superfamily 
member 1b (Tnfrsf1b (Tnfr2)). Relative to WT, Tnf KO mice exhibited reduced time spent in 
locomotion and increased time spent grooming in an open field, and reduced percent time on the 
open arms of an elevated plus maze; these phenotypes are consistent with Tnf KO leading to 
increased anxiety. The same study reported that, relative to WT, KO mice exhibited decreased 
immobility in the FST (Yamada et al., 2000). Mice that were null mutant for Tnfr1 also exhibited 
decreased immobility in both the FST and TST, relative to WT (Kaster et al., 2012). Mice that were 
null mutant for Tnfr1 and Tnfr2 exhibited reduced anxiety in the light-dark box test (and reduced 
social aggression in the resident-intruder test), relative to WT (Patel et al., 2010).  
 When mice are treated with an infectious agent that stimulates a pro-inflammatory immune 
response and a period of sickness (see section 2.5.), this is followed by depression-relevant 
behaviours including decreased sucrose preference. TNF is proposed to be a major mediator of these 
neurobehavioural effects of the pro-inflammatory immune response (Dantzer et al., 2008). Sickness 
can be induced by intracerebroventricular (i.c.v.) infusion of TNF. That this effect of TNF is mediated 
by TNFR1 was demonstrated by Tnfr1 KO mice being resistant to i.c.v. TNF-induced sickness, whereas 
both Tnfr2 KO and WT mice were fully responsive (Palin et al., 2009). Infusion of i.c.v. TNF led to 
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increased immobility in the FST and TST without altering locomotor activity in an open field test 
(Kaster et al., 2012). 
 Therefore, it has not yet been established whether the TNF SNP associated with depression is 
functional and, if so, whether the risk polymorphism leads to increased or decreased TNF activity. At 
the protein level, there is evidence that TNF is increased in depression. In mouse, reduced TNF 
signaling has been demonstrated to either increase or decrease anxiety, to reduce immobility in FST 
and TST, and to reduce social aggression. Increased TNF activity is also a major characteristic of 
mouse models in which an induced pro-inflammatory response leads to depression-relevant 
behaviour. 
 
3.3.10. Neuropeptide Y (mouse nomenclature: Npy; protein: NPY)  
The NPY gene encodes neuropeptide Y, a 36-amino acid neuropeptide/neurotransmitter localized in 
the CNS and autonomic nervous system (ANS). Two SNPs have been identified in NPY that are 
associated with depression: One SNP (rs16147) is a T-C polymorphism in the promoter region of NPY 
that leads to inclusion of a different amino acid in preproNPY signal peptide; the T polymorphism is 
associated with depression. The other SNP (rs16139) is also a T-C polymorphism and here it is the C 
that is associated with depression. The study which described these associations also described 
reduced CSF NPY levels in the depressed patients relative to control probands, suggesting that the 
risk polymorphisms are associated with decreased NPY activity (Heilig et al., 2004) (Table 1). Another 
study demonstrated an association of the rs16147 SNP with depression in a GxE interaction, where 
the environmental factor was early life stress (Sommer et al., 2010). Measurement of NPY mRNA in 
postmortem ACC tissue from depressive and control probands demonstrated that the rs 16147 T-
allele was associated with decreased NPY expression (Sommer et al., 2010). The 
endophenotype/state marker approach has been applied to NPY and its association with depression: 
in healthy subjects studied with fMRI, probands with a NPY-haplotype associated with low NPY 
expression demonstrated relatively high mPFC activation to negatively valenced words. Furthermore, 
probands with low-expression NPY-haplotype reported more negative affect in response to a pain-
stress challenge (Mickey et al., 2011). 
 NPY is a key example of a gene for which investigation into its association with depression 
was stimulated by the evidence for NPY regulation of emotion/stress, as obtained in animal studies. 
Npy is expressed in rat and mouse CNS in hypothalamus, neocortex, hippocampus and amygdala, and 
is mainly located in inhibitory GABA interneurons. Furthermore, within the amygdala and 
hippocampus, exogenous NPY exerts an anxiolytic effect (Heilig et al., 2004). Neuropeptide Y levels 
are increased by repeated stress, suggesting that up-regulation of Npy expression could contribute to 
stress coping (Heilig et al., 2004). Male Npy KO mice exhibited increased percent time spent on the 
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open arms of an elevated plus maze relative to WT, whereas there was no effect of genotype in 
females (Painsipp et al., 2011). In the same study, in the FST, both male and female Npy KO mice 
exhibited increased floating/immobility and decreased swimming and climbing, relative to WT. There 
was no effect of Npy KO on locomotor activity in the open field in this study (Painsipp et al., 2011). 
Neuropeptide Y exerts its anxiolytic effects through post-synaptic receptor 1 (NPY1R) in the 
amygdala; however, it also exerts anxiogenic effects via pre-synaptic receptor 2 (NPY2R) in the 
amygdala. Accordingly, the effects of Npy KO on mouse emotional behaviour would be expected to 
be complex, as indeed would NPY modulation of human emotional behaviour. Using a combination 
of conditional Npy2r KO mice and viral vectors to induce knockout, the effects of Npy2r KO in specific 
amygdala nuclei could be investigated (Tasan et al., 2010). Deleting Npy2r expression in the central 
amygdala also resulted in reduced NPY2R, presumably pre-synaptic, in central amygdala projection 
regions, including bed nucleus of the stria terminalis, nucleus accumbens and locus coeruleus. 
Behaviourally, such a deletion of NPY2R resulted in mice spending increased percent time on the 
open arms of an elevated plus maze, increased percent time in the light compartment of the light-
dark test, and decreased immobility in the TST. These findings suggest that pre-synaptic NPY2R 
inhibits GABA and/or NPY release from interneurons and/or projection neurons of the central 
amygdala and thereby exerts a net anxiogenic effect on behaviour under acute environmental 
challenge (Tasan et al., 2010).  
 Integrating the human and mouse evidence suggests that decreased NPY levels are a risk 
factor for anxiety and depression and that a net increase in NPY2R- relative to NPY1R-signaling  
increases anxiety- and depression-relevant behaviour.  
 
3.3.11. Noradrenaline transporter (mouse nomenclature: Slc6a2; protein: NET)      
Noradrenaline transporter (NET) is synthesised by noradrenaline (NE) neurons and is located on NE 
axon terminals where it performs pre-synaptic reuptake of NE and thereby is a major regulator of NE 
level and post-synaptic receptor binding in the synaptic cleft. Association of SLC6A2 with depression 
has been reported using the candidate gene approach: A T-G SNP (rs5558) leads to inclusion of a 
different amino acid, and the G allele leads to increased NET density and NA uptake. The G allele was 
also associated with increased risk of depression (Haenisch et al., 2008). When all identified SLC6A2 
SNPs were assessed in a GWAS-depression sample, the proportion of SNPs that exhibited an 
association with depression was statistically greater than would be expected by chance (Bosker et al., 
2011) (Table 1).  
  Extrapolating from the human evidence for an association between genetically-determined 
high NET activity and depression, it can be hypothesised that Slc6a2 over-expression and Slc6a2 KO 
will increase and decrease depression-relevant phenotypes, respectively. To our knowledge, there 
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are no studies of Slc6a2 over-expressing mice to-date, whereas a null mutant Slc6a2 mouse has been 
generated. In two studies it was demonstrated that Slc6a2 KO mice exhibited reduced immobility in 
the FST (Perona et al., 2008; Xu et al., 2000) and TST (Perona et al., 2008) relative to WT and one 
study reported no effect of the null mutant in FST (Haller et al., 2002).  Using a GxE design, the latter 
study also reported that Slc6a2 KO x chronic social defeat mice exhibited decreased immobility in the 
FST relative to WT x chronic social defeat mice (Haller et al., 2002). A similar approach was used in a 
second study (Haenisch et al., 2009): KO and WT mice were included in GxE experiments with either 
physical restraint stress or chronic social defeat as stressor and a non-stressed control condition. 
Using FST as readout, in the non-stressed group, KO mice exhibited reduced immobility relative to 
WT mice. Within genotype, restraint stress or chronic social defeat stress increased immobility in WT 
but not in KO mice. Using sucrose preference test as a read out, in the non-stressed group, KO mice 
exhibited increased sucrose preference relative to WT mice. Within genotype, restraint stress or 
chronic social defeat stress decreased sucrose preference in WT but not in KO mice. Using a social 
interaction test as readout, chronic social defeat decreased time spent in the social interaction zone 
in WT but not in KO mice. These studies indicate that Slc6a2 KO led to endophenotypes of reduced 
acute stress-induced immobility and increased reward sensitivity, and to stress resistance in terms of 
maintaining these phenotypes under the chronic stress conditions that led to depression-relevant 
phenotypes in mice expressing Slc6a2 (Haenisch et al., 2009).  
 The evidence for Slc6a2 KO mice is striking in terms of the magnitude of the G and GxE 
effects demonstrated. Null mutants display endophenotypes of increased interest in sucrose and 
decreased immobility (antidepressant-like) in the FST and TST. Furthermore, it confers resilience 
against the effects of chronic stress on interest in sucrose and mobility in the FST.  Studies with 
Slc6a2 HET mice will be important, as will development of a Slc6a2 over-expressing model, to link 
mice findings to the human evidence that NET hyper-activity is a risk factor for depression, and 
indeed that blocking of NET (Bymaster et al., 2005) is a current antidepressant mechanism of action, 
with stimulatory effects on psychomotor activity, arousal and attention being proposed to be 
important in this respect (Dell'Osso et al., 2011). 
 
3.3.12. Opioid-binding protein/cell adhesion molecule-like (mouse nomenclature:  Opcml; protein: 
OPCML) 
Opioid-binding protein/cell adhesion molecule-like (OPCML) protein is concentrated in the CNS and 
often co-localised with 5-HT and GABA. OPCML protein is necessary for coupling between opioid 
receptors and G-proteins and is therefore integral to opioid signalling and the acute and chronic 
effects of opioids (Schol-Gelok et al., 2010). An association between OPCML polymorphism and 
depression was reported based on a combined linkage-analysis and GWAS approach. An A-G SNP in 
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the intronic region of OPCML was differentially associated with depression, with the AG genotype 
conferring increased depression risk (Schol-Gelok et al., 2010) (Table 1). To our knowledge, there 
have been no mouse studies of the effects of manipulation of the Opcml genotype on brain or 
behaviour to-date.  
 
3.3.13. FK506 binding protein 5 (mouse nomenclature: Fkbp5; protein: FKBP5)  
Based on the corticosteroid hypothesis of depression (De Kloet et al., 2005; Holsboer, 2000), a 
considerable number of studies have been conducted into the association of the two corticosteroid 
receptors, mineralocorticoid receptor (MR) and glucocorticoid receptor (GR), with depression. Whilst 
there have been original reports of SNP association with the disorder for each of the receptors (e.g. 
(Spijker and van Rossum, 2009)), replication studies have not yet been conducted to an extent that 
would justify inclusion in candidate gene meta-analysis. Corticosteroid receptor function is regulated 
by chaperone proteins forming a molecular hetero-complex, and one such protein is FK506 binding 
protein 5 (FKBP5), coded by FKBP5. FKBP5 acts as an inhibitor of GR function. Several SNPs in FKBP5 
have been demonstrated to be associated with altered post-stress recovery of cortisol levels to 
baseline via the GR-mediated negative feedback loop. Furthermore, there are reports that the same 
SNP variants that predispose to such hyper-cortisolism are associated with depression risk, although 
other studies have not replicated this association (Zimmermann et al., 2011). In a prospective study, 
five FKBP5 SNPs were demonstrated to be associated with depression, not as a genetic main effect 
but in interaction with trauma, defined as events that caused intense fear, helplessness or horror 
(Zimmermann et al., 2011) (Table 1). 
 Given that FKBP5 inhibits GR function and that GR mediates the effects of the high cortisol 
levels induced by stress, including post-stress cortisol decreases via negative feedback, then the 
potential effects of SNPs that induce changes in FKBP5 structure-function are difficult to predict. On 
the one hand, decreased FKBP5 activity would be expected to increase GR transactivation; on the 
other hand, increased GR transactivation would be expected to accelerate the negative feedback 
loop leading to recovery of basal cortisol levels. Mice deficient of FKBP5 have been generated and 
compared with WT littermates (Touma et al., 2011). In the FST, there was no effect of Fkbp5 KO per 
se. However, when mice were exposed to restraint stress followed by a FST and then at 24 hours to a 
second FST, KO mice exhibited increased swimming and decreased floating relative to WT at the 
second FST specifically. There was no effect of Fkbp5 KO on behaviour in an open field test, elevated 
plus maze test or light-dark box test. The corticosterone response to restraint stress was reduced in 
Fkbp5 KO mice relative to WT.  
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 From these findings it can be tentatively concluded that a lack of FKBP5 leads to increased 
stress resistance, such that polymorphisms of FKBP5 that increase FKBP5 activity could lead to 
increased stress sensitivity and be a risk factor for depression. 
 
3.3.14. Corticotropin releasing hormone receptor 1 (mouse nomenclature: Crhr1; protein: CRHR1) 
Intimately related to the corticosteroid hypothesis of depression (see above) is the hypothesis that 
corticotropin releasing hormone (CRH) is a causal factor in depression. CRH in the hypothalamus acts 
as a neurohormone to stimulate corticotrophin release from the pituitary gland, which in turn 
stimulates corticosteroid release from the adrenal gland. CRH is also synthesized in several limbic 
regions of the CNS and functions as a neurotransmitter (Berton and Nestler, 2006). Two G-protein 
coupled receptor proteins are receptors for CRH, namely CRH receptor 1 and 2. CRHR1 is expressed 
post-synaptically and mediates the excitatory effects of CRH on emotional and stress responses 
(Berton and Nestler, 2006). The reporting of increased CRH levels in the cerebrospinal fluid of 
depressed versus control subjects (Nemeroff et al., 1984) stimulated interest in CRH and its receptors 
with respect to depression aetio-pathology (Nemeroff, 1996). With respect to CRHR1 polymorphism 
and its association with depression, there have been no reports for genetic main effects, but certain 
SNPs have been reported to be associated with depression in interaction with environmental 
stressors, most notably abuse experienced during childhood, in retrospective studies (Bradley et al., 
2008; Grabe et al., 2010). Furthermore a GxGxE interaction on depression has been reported for 
CRHR1 SNPs, 5-HTTLPR VNTR (S, L) and childhood abuse (Ressler et al., 2010) (Table 1). 
 Null mutant Crhr1 mouse models have been generated. Null mutant Crhr1 mice exhibited 
unchanged basal and decreased stress-induced corticotrophin and corticosterone levels relative to 
WT and HET (Smith et al., 1998; Timpl et al., 1998). The KO mice exhibited increased locomotor 
activity in an open field (Timpl et al., 1998) or no change in locomotor activity in an open field (Smith 
et al., 1998), relative to WT and HET mice. The KO mice exhibited reduced latency to enter and 
increased time spent in the light compartment in a light-dark box test relative to WT and HET mice 
(Smith et al., 1998; Timpl et al., 1998). The KO mice exhibited increased percent time on the open 
arms of an elevated plus maze relative to WT mice (Smith et al., 1998). There was no phenotypic 
differences between HET and WT mice on these endocrine and behavioural measures (Smith et al., 
1998; Timpl et al., 1998). In a separate study (Lu et al., 2008), there was no effect of Crhr1 KO relative 
to WT on percent time spent immobile in the FST. When the FST was preceded by restraint stress, 
WT mice exhibited decreased immobility relative to non-stressed WT mice whereas there was no 
effect of the restraint stress in KO mice; furthermore, stressed Crhr1 KO mice exhibited increased 
immobility relative to stressed WT mice. These findings suggest, somewhat unexpectedly, that Crhr1 
mediates active behavioural responses to acute stressors (Lu et al., 2008). Using contextual fear 
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conditioning it was demonstrated that mice in which Crhr1 KO was specific to the limbic forebrain 
exhibited reduced long-term fear memory relative to WT mice. In addition to this behavioural 
phenotype, the KO mice exhibited absence of the long-lasting increase in AMPA receptor signalling in 
the dentate gyrus of the hippocampal formation that was observed in WT mice (Thoeringer et al., 
2012).  
 In line with the hypothesis that hyper-activity in CRH-CRHR1 signaling can lead to depression-
relevant phenotypes, mice constitutively over-expressing Crh have been engineered. Such mice 
exhibit hyper-corticoidism and develop an overall phenotype that is analogous to Cushing’s 
syndrome. To achieve more controlled increases in CRH-CRHR1 signaling, a conditional mouse model 
was generated in which Crh over-expression was specific to the CNS (Lu et al., 2008). Relative to 
control mice, homozygote and heterozygote CNS-Crhr1 over-expressing mice exhibited, somewhat 
unexpectedly, reduced immobility in the forced swim test. Increased noradrenergic signaling due to 
CRHR1-mediated hyper-activation of the locus coeruleus was proposed as a mediating mechanism 
(Lu et al., 2008). 
 Despite the elegant molecular-genetic manipulation studies conducted with Crhr1 and Crh 
mouse models to-date, there has been only limited progress in linking findings to the human 
evidence for increased CRH-CRHR1 signaling in depression, such that it is parsimonious to conclude 
that increased CRH-CRHR1 signaling is not causally involved in the pathogenesis of depression. 
However, it also needs to be stated that the lack of validity of the readout tests used to-date, such as 
the FST, means that concluding statements must be tentative.  
 
3.3.15. Brain-derived neurotrophic factor (mouse nomenclature: Bdnf; protein: BDNF) 
Brain-derived neurotrophic factor (BDNF) is the most abundant and widely-distributed neurotrophin 
in the CNS. BDNF promotes neurogenesis, neuronal survival, axonal and dendritic growth, and 
synapse formation, both in the developing and adult CNS. BDNF expression is decreased in the post 
mortem hippocampus of depressed (suicide) patients relative to controls (Duman and Monteggia, 
2006). A common G-A SNP (rs6265) in the BDNF gene results in an amino acid change from valine to 
methionine in the prodomain at codon 66 (Val66Met). In neuronal culture systems, relative to 
BDNFVal, BDNFMet resulted in a decreased distribution of BDNF to neuronal dendrites and decreased 
activity-dependent BDNF secretion, possibly reflecting relatively reduced interaction of BDNFMet with 
a sorting protein (Chen et al., 2006). Humans carrying the G (Met) allele exhibit depression-relevant 
endophenotypes relative to A (Val) carriers, including smaller hippocampal volume and deficits on 
hippocampal-dependent memory tasks (Chen et al., 2006), and a deficit in the extinction learning of 
conditioned fear responses that is associated with greater amygdala reactivity (Soliman et al., 2010).  
With respect to association of this BDNF polymorphism with depression, there have been no reports 
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for genetic main effects, but GxGxE interaction effects have been reported. In a child study of 
depression, assessed using the Mood and Feelings Questionnaire, in abused/neglected 
(maltreatment) children relative to control children (Kaufman et al., 2006), there was a significant 
interaction between BNDF Val/Met genotype, 5-HTT S/L genotype and maltreatment status. 
Depression scores were greater in Met x SS carriers who had experienced maltreatment than in 
children in other GxGxE groups (Table 1). 
 There is no mouse orthologue of the BDNF polymorphism underlying Val66Met. BDNFMet 
knock-in mice have been generated (Chen et al., 2006). BdnfMet/Met and Bdnf+/Met mice exhibited 
normal BDNFMet expression in the brain, but the regulated secretion of BDNFMet from neurons was 
defective, resulting in a decrease in available BDNF in BdnfMet/Met mice. BdnfMet/Met and Bdnf +/Met mice 
exhibited decreased hippocampal volume compared to WT, a finding that is analogous to human 
studies. BdnfMet/Met mice exhibited a reduced number of entries into and percent time spent in the 
centre of an open-field, and reduced percent entries onto and percent time on the open arms of an 
elevated plus maze, in comparison to WT. Bdnf +/Met did not exhibit such increased anxiety-relevant 
behavior. Mice that were partial knockout for Bdnf (Bdnf +/-) exhibited anxiety phenotypes similar to 
those of BdnfMet/Met mice (Chen et al., 2006). In a separate study, the effects of BdnfMet knock-in were 
studied on extinction learning of conditioned fear conditioning (Soliman et al., 2010). Whilst there 
was no effect of genotype on fear conditioning, there was a dose-response inhibitory effect of 
BdnfMet on extinction learning, with a greater continued expression of freezing behaviour to the CS in 
the absence of the US. Bdnf knock-out mice have also been generated. In one study, HET mice 
exhibited less locomotion than WT (Hall et al., 2003). In a separate study, no differences were 
observed between HET and WT mice in activity or anxiety behavior assessed in an open-field and 
elevated plus maze test, respectively. There was also no genotype effect in the sucrose preference 
test or FST (MacQueen et al., 2001). In the US pre-exposure test (one group of mice exposed to 
inescapable electroshocks (IS) and the other group to no shocks (NS)), HET-IS mice exhibited an 
increased escape latency relative to WT-IS mice. However, HET mice also exhibited reduced pain 
sensitivity in a hot plate test, such that reduced nociception could have contributed to the escape 
deficit observed (MacQueen et al., 2001). Mice with forebrain-specific knockout of the trkB receptor, 
the main mediator of BDNF signaling, exhibited stereotyped hyper-locomotion relative WT, but no 
phenotype in the FST or elevated plus maze test (Zörner et al., 2003). Transgenic mice overexpressing 
the dominant-negative form of trkB, resulting in reduced activation of trkB, did not differ from WT in 
time spent immobile in FST (Saarelainen et al., 2003). 
 Thus, there is some converging evidence for humans and knock-in mice that BdnfMet and the 
resultant decrease in BDNF availability is associated with decreased hippocampal volume and 
impaired extinction of conditioned fear responses. However, in studies with BDNF KO or trkB KO 
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mice there was no phenotype in terms of sucrose preference or immobility in the FST. It will be 
important to conduct further studies to clarify this issue: firstly, BDNF is hypothesized to be an 
important mediator of current antidepressant mechanisms of action (Martinovich et al., 2007), and 
furthermore, for putative novel antidepressants, notably the glutamate NMDA-receptor-antagonist 
ketamine, a central role for BDNF in the mechanism of action is proposed (Duman et al., 2012).   
 
3.4. Mouse models for the study of stress effects on brain region-specific gene expression 
Post mortem transcriptome-level studies of altered gene expression in specific regions of the brain 
from depressed versus healthy control subjects have yielded important findings, as summarized 
above (section 2.5, Table 2). Mouse models in which environmental stress has been demonstrated to 
lead to depression-relevant behavioural effects provide important opportunities for ex vivo 
transcriptome (mouse microarray) or candidate gene studies of altered gene expression. Such ex vivo 
mouse model studies can be aimed at replicating human findings as a validation step and at 
identifying novel genes and pathways that exhibit stress-dependent changes in expression in specific 
brain regions. In this section we describe a prominent example of a study for each of these two 
approaches.  
 As described above (section 2.5), one study (Sibille et al., 2009) assessed gene expression 
changes in parallel in depressed subjects and mice exposed to chronic unpredictable stress (CUS). 
The mice (BALB/c) were exposed to CUS for 7 weeks, and the regimen consisted of repetitions of 
single caging, exposure to rat or cat faeces or water in the home cage, tilting or shaking the home 
cage, placement in an empty cage of a conspecific, and altering length and time of the light-dark 
cycle. Behavioural effects of CUS were increased latency to begin feeding in a novelty-suppressed 
feeding test, and decreased latency to attack an intruder in a resident/intruder test. Gene expression 
effects were assessed using mouse microarray on mRNA isolated from cingulate cortex (including 
part of the prelimbic cortex), amygdala and dentate gyrus. Each of the three regions exhibited 
altered gene expression in 150-300 genes, but very few genes exhibited altered expression in two 
regions and none did so in all three regions (Sibille et al., 2009; Surget et al., 2009). A relatively large 
number of genes that exhibited altered expression have a demonstrated association with depression 
and/or antidepressant mechanism of action. This included genes coding for components of 
neurotransmitter systems (GABA, glutamate, and peptides), signal-transduction pathways (protein 
kinase C (PKC) genes, phospholipase C (PLC) genes, and mitogen-activated protein kinase (MAPK) 
genes) or second messenger systems (cyclic adenosine monophosphate), and a large number of 
oligodendrocyte markers (e.g. Mobp, Pllp, Gpr37) (see Table 2 and Table 4). These genes exhibited 
altered expression in human depression and the mouse CUS model primarily in amygdala, and it is 
possible that the regions of cingulate cortex sampled were not analogous between the two species. 
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 A second mouse model investigation into stress effects on gene expression studied chronic 
social defeat in C57BL/6 mice, and brain regions of interest were within the mesolimbic dopamine 
circuit, namely nucleus accumbens and ventral tegmental area (Krishnan et al., 2007). Chronic social 
defeat (CSD) involved 10-min per day physical exposure to and attack by an aggressive ex-breeder 
male CD1 mouse, and olfactory, visual and auditory exposure to the CD1 mouse for the remainder of 
the day. This was repeated over 10 days and a different CD1 mouse was used on each day. 
Behavioural effects of CSD were reduced time in proximity of a CD1 mouse in a social interaction 
test; approximately half of the CSD mice exhibited this effect relative to controls, and these mice 
were described as CSD susceptible (SUS), in contrast to CSD unsusceptible (UNS). The SUS mice also 
exhibited reduced sucrose preference in a sucrose preference test and a hyperthermic response 
when exposed to a CD1 mouse. Both SUS and UNS mice exhibited decreased percent time on the 
open arms of an elevated plus maze and increased serum corticosterone response to forced 
swimming, relative to control mice. BDNF was measured as a candidate protein and exhibited 
increased expression in nucleus accumbens in SUS mice relative to UNS and control mice. With 
respect to gene expression, of particular interest here are genes that exhibited altered expression in 
SUS versus control mice but not in UNS (or at least not in the same direction as SUS) versus control 
mice. In the nucleus accumbens, this included the genes adenylyl cyclase isoform 7 (Adcy7), ciliary 
neurotrophic factor (Cntf), histone deacetylase 2 (Hdac2), Homeo box B3 (Hoxb3), runt-related TF-1 
(Runxltl) and phospholipase C gamma-2 (Plcg2), which were up-regulated, and Homer homolog 3 
(Homer3), which was down-regulated. In the ventral tegmental area, this included the genes galanin 
(Gal) and wingless-related MMTV site 2 (Wnt2) which were up-regulated, and NEL-2 like (Nell2), 
which was down-regulated, in SUS versus control mice specifically (Krishnan et al., 2007) (Table 4).   
     (TABLE 4 ABOUT HERE) 
Given that the two studies reviewed above were conducted with different mouse strains and 
investigated the effects of different chronic stressors on the transcriptome in different brain regions, 
then the lack of concordance between their respective findings is not too surprising. The study by 
Sibille et al. identified genes from several functional classes (see Table 2) that exhibited similarly 
altered expression in the amygdala in Balb/c mice that had experienced CUS and in human 
depression relative to their respective comparison groups. It will be important to conduct further 
such studies using C57BL/6 mice, the background strain for most behavioural genetic models, given 
that the amygdala demonstrates significant mouse-human homology in both structure and function 
and is a brain region that is central to emotional processing and exhibits altered functioning in 
depression.  
 
3.5. Mouse models for genes exhibiting brain region-specific altered expression in depression 
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So far, we have considered (1) mouse models for polymorphism-depression associations, based on 
gene knock-out, knock-in and overexpression approaches, and (2) mouse models for CNS region-
specific up- or down-regulation of gene expression in depression, based on stress manipulations and 
ex vivo transcriptome quantification. In this third and final section, we consider (3) mouse models for 
CNS region-specific up- or down-regulated gene expression in depression, based on gene knockout 
and over-expression approaches. For this, three genes are presented that were identified as 
exhibiting significantly altered expression in the region of interest using transcriptome-level analysis 
with appropriate statistical stringency; namely, urocortin 3, forkhead box D3 and cannabinoid 2 
receptor ((Kang et al., 2007); see section 2.5 and Table 2).    
 
3.5.1. Urocortin 3 (Stresscopin) (mouse nomenclature: Ucn3; protein: UCN3) 
Stresscopin is a member of the CRH neuropeptide family and a selective ligand for CRH receptor 2 
(CRHR2). Expression of UCN3 was increased in dlPFC in depressed relative to control subjects (Kang 
et al., 2007) (section 2.5. and Table 2). In mouse, UCN3 is expressed in neurons mainly in brain 
regions involved in stress processing, including  paraventricular nucleus  of hypothalamus (PVN), bed 
nucleus of the stria terminalis (BNST) and basomedial nucleus of amygdala (Venihaki et al., 2004). In 
C57BL/6 mice, 3 h physical restraint induced increased Ucn3 expression in the PVN with no change in 
the amygdala (Venihaki et al., 2004) (Table 4). Intracerebroventricular (i.c.v.) injection of UCN3 in 
C57BL/6 mice resulted in an increase in amount of activity and percent time spent in the centre of an 
open field compared to mice injected with vehicle. It also led to a decreased latency to enter the light 
compartment in a dark-light box test compared to vehicle mice. These findings suggest that i.c.v. 
injection of UCN3 is anxiolytic (Venihaki et al., 2004). Whilst to our knowledge there are no published 
studies of over-expressing or null mutant Ucn3 mice, null mutant Crhr2 mice have been generated to 
study the effects of neutralising the CRH neuropeptide family ligands of this receptor, including Ucn3. 
Relative to WT, in an open field test, Crhr2 KO mice exhibited less activity and time spent in the inner 
quadrant. In an elevated plus maze test, Crhr2 KO mice entered less frequently and spent less 
percent time on the open arms, compared to WT mice. No effect of genotype was detected in the 
light-dark box test. These findings suggest that UCN3 and other CRHR2 ligands are anxiolytic. Male 
and female Crhr2 KO mice exhibited increased immobility relative to WT in the FST, indicating that 
lack of CRHR2 exerts the opposite effect to that of current antidepressants (Bale and Vale, 2003). 
Given the mouse findings that UCN3 is anxiolytic, that this effect is mediated by CRHR2, and that lack 
of CRHR2 increases immobility in the FST, the mouse evidence does not support a causal link 
between increased dlPFC UCN3 expression in depression and pathogenesis. It is possible that 
increased UCN3 expression in depression is a component of the mobilization response to stressful 
environments that are risk factors for depression. 
36 
 
 
3.5.2. Forkhead box D3 (mouse nomenclature: Foxd3; protein: FOXD3) 
FOXD3 is a member of the forkhead family of transcription factors that is involved in the 
development of the vertebrate neural system, including the promotion of neural crest cell fate, 
migration and differentiation of neural crest cells, as well as in regulation of tissue-specific gene 
expression, embryogenesis and tumorigenesis (Kang et al., 2007). In a post mortem GW expression 
study of the DLPFC (BA9), FOXD3 mRNA expression was increased in the gray matter of depressed 
subjects relative to controls (Kang et al., 2007)  (section 2.5. and Table 2). To our knowledge there 
are no studies of over-expressing or null mutant Foxd3 mice. The study that reported the increased 
expression of DLPFC FOXD3 in depression also reported increased Foxd3 expression in the PFC of 
Sprague Dawley rats exposed to chronic unpredictable stress relative to non-stressed controls (Kang 
et al., 2007).  
 
3.5.3. Cannabinoid 2 receptor (mouse nomenclature Cnr2; protein: CNR2, CB2) 
The cannabinoid receptor 2 (CNR2, CB2) is expressed by cells in immune tissues and also in the CNS, 
by microglia, astrocytes and certain neuronal subpopulations (Fernandez-Ruiz et al., 2006). CNR2 
functions include regulation of CNS cell responses to inflammatory and degenerative stimuli, by 
reducing the production of various cytotoxic factors such as cytokines, nitric oxide and reactive 
oxygen species (Fernandez-Ruiz et al., 2006). In a post mortem GW expression study of the DLPFC 
(BA9), CNR2 expression was increased in depressed relative to control subjects (Kang et al., 2007) 
(section 2.5. and Table 2). 
 Mouse model studies have contributed to the evidence that Cnr2 expression is induced by 
neuroinflammatory signals, with Cnr2 levels increasing in microglia and astrocytes in response to 
inflammation (Kang et al., 2007). In mouse CNS cultures, CNR2 binding activates the MAPK/MAPKK 
signaling pathway and thereby reduces pro-inflammatory cytokine levels (Molina-Holgado et al., 
1997) and increases neuronal survival (Benito et al., 2008). In BALB/c mice exposed to chronic mild 
stress, Cnr2 expression was increased in whole brain preparations relative to those from control mice 
(Onaivi et al., 2008) (Table 4).  
 Mice have been generated that over-express Cnr2 in neurons and glia specifically (CB2xP).   
There was no effect of over-expression in an open field test relative to WT in terms of total 
locomotor distance, but CB2xP mice did exhibit increased central locomotor distance and decreased 
peripheral locomotor distance relative to WT. In a light-dark box test, CB2xP mice spent more time in 
the light box than did WT. In an elevated plus maze, CB2xP mice spent increased percent time on the 
open arms relative to WT. In a tail suspension test (TST), CB2xP mice exhibited reduced immobility 
compared to WT. Following chronic mild stress, there was no difference between CB2xP and WT 
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mice in either the TST or a sucrose consumption test (Romero-Zerbo et al., 2012). Null mutant Cnr2 
mice have been generated: such KO mice exhibited decreased total locomotor distance and 
decreased activity in the centre of an open field, relative to WT (Flake and Zweifel, 2012). In BALB/c 
mice, ICV injection of Cnr2 antisense oligonucleotide led to increased percent time spent on the open 
arms in an elevated plus maze test relative to controls that were injected with sense or mismatch 
oligonucleotides, a finding consistent with Cnr2 inactivation exerting an anxiolytic effect (Onaivi et 
al., 2006).  
 Therefore, there is evidence that CNS-specific Cnr2 over-expression leads to anxiolytic and 
antidepressant-like effects in mice, which contradicts the interpretation that the increased DLPFC 
CNR2 expression observed in depression is directly relevant to depression aetio-pathology. However, 
it is nonetheless possible that increased CNR2 expression represents a biomarker for pro-
inflammatory processes that could be pathological in depression. 
 
4. Mouse models of the genetics of depression: Critical assessment of the experimental designs 
used and evidence obtained 
As reviewed above, current evidence for the genetic aetiology and pathogenesis of depression is 
scant and there are a number of reasons for this, major among them being: the complexity and 
heterogeneity of depression psychopathologies; the current lack of diagnostic neuropathologies; the 
small number of GWAS or CGCC studies to-date of depression-relevant endophenotypes in healthy 
subjects; the low penetrance of specific alleles for depression, specific symptoms of depression and 
probably even specific depression-relevant endophenotypes; the importance of environment-
induced physiological-neurobiological processes (E) for depression aetio-pathology; the lack of 
studies to-date of GWAS GxE interaction for depression and specific depression symptoms and state 
markers; the small number of studies to-date of cGxE for depression and specific depression 
symptoms and state markers; the small number of studies to-date of GW up- or down-regulation of 
gene expression in depression-relevant brain regions/circuits and subsequent studies of gene hits.  
 Given the limited progress to-date in establishing which genes are central to depression 
aetio-pathology and via what mechanisms, it is only to be expected that there has been little major 
progress in terms of generating mouse models that provide convincing evidence for the involvement 
of specific genes in the regulation of depression-relevant phenotypes. Nonetheless, there are some 
examples of where mouse models of human descriptive evidence have provided convincing 
supportive causal evidence, and demonstrate that the translational-genetic approach does indeed 
have potential for increasing understanding of the aetio-pathogenesis of depression. Here we would 
highlight the evidence that a SLC6A2 SNP that leads to increased NET activity is associated with 
increased risk of depression (Haenisch et al., 2008) (Table 1), and that Slc6a2 KO mice exhibited 
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endophenotypes of decreased immobility in the FST and increased sucrose preference, and resilience 
to the effects of environmental stress observed in WT mice in terms of reduced sucrose preference 
and increased social avoidance (Haenisch et al., 2009). Another highlight would be the evidence that 
a BNDF SNP leading to BDNFMet leads in human to endophenotypes of decreased hippocampal 
volume/function and impaired extinction of learned fear/increased amygdala reactivty and to 
increased levels of depression-relevant psychological state markers in interaction with the 5-HTTLPR 
S allele and early life stress (Chen et al., 2006; Kaufman et al., 2006; Soliman et al., 2010), and that 
BdnfMet knock-in mice exhibited increased anxiety in an elevated plus maze and a deficit in extinction 
learning in fear-conditioned freezing (Chen et al., 2006; Soliman et al., 2010).  
 Of course, the human-mouse model research approach is not unidirectional and, in addition 
to the reverse genetics approach, study of the effects of aetiologically-valid environmental 
manipulations on brain region-specific transcriptome expression in mice i.e. the forward genetics 
approach, has great potential for candidate gene and signaling-pathway discovery in depression 
aetio-pathogenesis. One important example here is the study that compared microarray gene 
expression changes in the amygdala in depressed humans versus healthy controls and in mice 
exposed to CUS versus non-manipulated controls (Sibille et al., 2009) (see sections 2.5. and 3.4. and 
Tables 2 and 4). Significant and bidirectional predictions of altered gene expression were 
demonstrated for the amygdala, and according to various criteria a core set of 32 genes, expressed in 
either glia or neurons, was identified (Sibille et al., 2009). These genes would appear to be important 
candidates for future human and mouse model studies. A second important example is the study 
that measured microarray gene expression changes in the nucleus accumbens and ventral tegmental 
area of mice that had been exposed to and exhibited depression-relevant behavioural effects of the 
environmental manipulation, chronic social defeat (Krishnan et al., 2007). 
 When discussing the progress made with and the limitations of mouse models of the genetics 
of depression, it is appropriate to also refer to the validity of the environmental manipulations and 
the readouts – primarily behavioural - that alongside the genetic manipulations constitute such 
models (Pryce and Seifritz, 2011). With respect to environmental manipulations, the current 
understanding of the characteristics of life events that render them stressful is limited, although 
there is evidence that major loss, humiliation, entrapment and uncontrollability are of high 
importance (Kendler et al., 2003). Uncontrollability is the basis of learned helplessness, which is an 
important aetio-pathological concept in preclinical and clinical depression research (Pryce et al., 
2011). With respect to behavioural tests, it is apparent from section 3.3 that a small number of tests 
have been used frequently to assess the behavioural effects of genetic manipulations; these are the 
sucrose preference test, forced swim test, tail suspension test and the elevated plus maze test. From 
section 3.2., it will be clear that, with the exception of the sucrose preference test, these are not the 
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tests with high validity with respect to modeling the psychopathology of depression. As noted, the 
FST and the TST are screening tests for acute effects of previous- and current-generation 
antidepressants, and this is the justification for including studies with these tests here, but an 
objective link between immobility in these tests and any neuropsychological state that characterizes 
depression is lacking. The elevated plus maze is a conflict-anxiety/anxiolytic screening test and 
studies using it have been included because of the high co-morbidity of anxiety disorders with 
depression. Clearly, the valid, translational tests of depression-relevant neuropsychological processes 
given in Table 3 need to be the focal readouts in future mouse models of behavioural effects of 
genetic and environmental manipulations (Pryce and Seifritz, 2011). 
 
5. Mouse models of the genetics of depression: considerations for future research 
The justification for the study of mice as models of depression is to increase understanding of the 
aetio-pathogeneis of depression. The ultimate aim of this increased understanding is to discover valid 
novel molecular therapeutic targets and, in a subsequent stage, to utilize mouse models to screen 
and develop novel, efficacious antidepressant pharmacotherapies or even combined psycho- and 
pharmaco-therapies. It has to be acknowledged that, to-date, a very substantial amount of research 
has been conducted with mice that is proposed to be depression-relevant but which in reality has 
yielded limited evidence and little progress. Why is this and are there grounds for optimism for 
future research efforts?  
 The major reasons for the lack of progress to-date include: 
 (1) As referred to above, the aetio-pathogenesis of depression is complex and the current 
poor understanding of it means that there has been little knowledge available to inform the design of 
valid mouse models. The GWAS and CGCC approaches have yielded negligible positive evidence in 
terms of understanding the causation of depression. Nonetheless, they have yielded extremely 
important negative evidence; namely, that the study of polymorphisms in single genes in isolation 
from other factors will not lead to increased understanding of the aetio-pathogenesis of depression. 
It is important to accept this negative evidence and not to invest further resources into carrying out 
even larger, more powerful studies, just to identify polymorphisms that are statistically significant 
but negligible in terms of their effect size and, therefore, in their relevance to the understanding of 
depression causality in the majority of patients. It is essential that the next generation of human 
studies aimed at increased understanding of depression aetio-pathogenesis uses the following three 
strategies: GWAS for physiological, neural and psychological risk states or endophenotypes for 
depression in healthy probands; a prospective genome-wide approach to GxE association studies for 
physiological, neural and psychological symptoms and state markers/intermediate phenotypes of 
depression; genome-wide expression profiling by specific cell type (e.g. neurons, astrocytes, 
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microglia, oligodendrocytes), also taking epigenetic processes into account, in key mediating brain 
regions in depression.  
 (2) Not until they are informed by the accurate and predictive descriptive evidence provided 
by human studies using the above three strategies, can valid mouse models be developed in order to 
test cause-effect hypotheses of direct relevance to depression aetio-pathogenesis. When evidence-
based mouse models are developed, should they fail to yield depression-relevant physiological, 
neural and psychological effects, then it must be concluded that the term, mouse models of 
depression, is an oxymoron. The explanation would be that a certain level of CNS complexity, 
inherent to primate- or even human-unique brain regions such as the granular frontal cortices (e.g. 
(Murray et al., 2011)), is necessary in order that an organism can demonstrate state markers of this 
medical condition. If, however, mouse models based on accurate and predictive evidence from 
human studies do yield depression-relevant physiological, neural and psychological effects, then such 
models can be utilized to increase understanding of the processes via which environmental factors 
impact on the body-brain connection and, within the brain, on region- and cell type-specific signaling 
pathways and gene transcription and translation. Furthermore, once validated reverse-genetics 
models were established, this would provide the justification for forward-genetics models and 
extrapolation of the evidence obtained therewith to human studies. 
 There are grounds for optimism, with respect to human depression research, mouse-model 
depression research, and therefore the essential bi-directional interaction between these: 
 (3) The importance of improved definition and understanding of the psychopathologies of 
depression and other mental disorders has been recognized, even to the extent of improving the 
definitions and descriptions of the affected emotional-cognitive processes in diagnostic classification 
(Insel et al., 2010; Soskin et al., 2012). This development will facilitate the study of psychological 
endophenotypes and psychopathological state markers/intermediate phenotypes, as well as the 
development of behavioural readouts in mice with objective face validity (e.g. (Pryce and Seifritz, 
2011)). Intimately related to this point is the need to take account of the heterogeneity of 
depression, both in terms of the diagnostic symptoms exhibited by individual patients and the 
differences in diagnostic symptoms between patients. The focus on individual symptoms will be 
commensurate with identification of underlying neuropsychopathology and, in turn, underlying 
genetic-environmental aetiology.     
 (4) The need for rigorous and replicated prospective genome-wide GxE studies and cGxE 
studies, before specific genes become the focus of subsequent human research and indeed mouse 
model research, is being recognized (e.g. (Duncan and Keller, 2011)). Genomic and proteomic 
technology is already advanced to an extent that allows for identification of polymorphisms at a 
deep-molecular level. The study of environmental life events is becoming better defined in terms of 
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what characteristics of the life event are of physiological and/or psychological relevance (Kendler et 
al., 2003), and in terms of the importance of the stage at which the environmental life event is 
experienced (Danese et al., 2010; Danese et al., 2007). There can be reasonable grounds for 
optimism that this approach will lead to the discovery of accurate and predictive evidence for the 
GxE aetiology of depression. This descriptive evidence can then be investigated in informed mouse 
GxE model experiments. 
  (5) Magnetic resonance imaging (MRI) studies are allowing for improved understanding of 
the brain regions and their inter-connectivity that underlie depression (Drevets et al., 2008; Mayberg, 
2003). This knowledge is allowing for increased understanding of the neuro-psychopathology of 
depression (Disner et al., 2011). This, in turn, will inform research into the brain regions which should 
be focused on in postmortem gene expression studies. Evidence on whether and how those genes 
that are up- or down-regulated in depression-relevant brain regions are related to the genes that are 
identified in genome-wide GxE studies will lead to the discovery of accurate and predictive evidence 
for the aetio-pathology of depression. This evidence can then be investigated in informed mouse 
model experiments, including the use of high-resolution MRI technology for the detailed functional 
study of the mouse brain (Rudin, 2009).  
 (6) The physiological systems that are being considered as body-brain mediators of the 
environmental aetiology are expanding beyond the HPA axis. Most interesting in this respect is the 
attention being given to the dynamic stress reactivity of the immune system (Dantzer et al., 2008). As 
noted above, of those few genes for which association with depression has been reported with some 
level of replication, several are directly or indirectly involved in the functioning of the immune 
system. The high homology of the mouse and human immune systems and the processes via which 
peripheral immune events can impact on the brain, means that mouse model studies here should be 
highly informative (Miller et al., 2009). 
 (7) Although based on serendipity rather than bi-directional human and animal model 
research, actual or potential new anti-depressant mechanisms of actions are being identified that 
provide potential insights into the aetio-pathology of depression. Important examples here are the 
dual-mechanism melatonin receptor agonist and serotonin 2C antagonist, agomelatine (de Bodinat 
et al., 2010), and the NMDA receptor antagonist, ketamine (aan het Rot et al., 2012). Of course, 
when a functioning bi-directional translational research strategy for novel anti-depressant therapies 
is put in place, then target discovery and validation and lead compound development will be 
hypothesis driven rather than based on serendipity, and genetic and genetic-environmental mouse 
models will be essential to this process. In these models, it is essential that the behavioural readout 
tests exhibit face and construct validity, of course. It is also important that they are commensurate 
with repeated testing and thereby allow for the assessment of gradual responsiveness to chronic 
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treatment. Readouts such as the learned helplessness effect and fear conditioned freezing are 
commensurate whereas screening tests such as the forced swim test are not.    
(8) Applying these methodological and conceptual advances, mice with their inherent 
advantages in terms of short generation interval, genomic mapping, molecular-genetic tractability, 
CNS and physiological complexity, environmental responsiveness and complex learning-motivational-
emotional systems, can make a significant, iterative contribution to increasing the inter-disciplinary 
scientific understanding of depression and its treatment.     
   
6. Acknowledgements 
This research was supported by the The Swiss National Science Foundation: grant 31003A-141137, 
the National Center for Competence in Research “Neural Plasticity and Repair” and the National 
Center for Competence in Research “Synapsy”. 
 
7. References 
aan het Rot, M., Zarate, C.A., Charney, D.S., Mathew, S.J., 2012. Ketamine for depression: where do 
we go from here? Biol Psychiatry 72, 537-547. 
Adamec, R., Burton, P., Blundell, J., Murphy, D.L., Holmes, A., 2006. Vulnerability to mild predator 
stress in serotonin transporter knockout mice. Behav Brain Res 170, 126-140. 
Alexander, N., Klucken, T., Koppe, G., Osinsky, R., Walter, B., Vaitl, D., Sammer, G., Stark, R., Hennig, 
J., 2012. Interaction of the serotonin transporter-linked polymorphic region and environmental 
adversity: increased amygdala-hypothalamus connectivity as a potential mechanisms linking neural 
and endocrine hyperreactivity. Biol Psychiatry 72, 49-56. 
Alexander, N., Kuepper, Y., Schmitz, A., Osinsky, R., Kozyra, E., Hennig, J., 2009. Gene-environment 
interactions predict cortisol responses after acute stress: implcations for the etiology of depression. 
Psychoneuroendocrinol 34, 1294-1303. 
Ansorge, M.S., Hen, R., Gingrich, J.A., 2007. Neurodevelopmental origins of depressive disorders. 
Curr Opin Pharmacol 7, 8-17. 
APA, 2000. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Revision  American 
Psychiatric Association, Washington, DC. American Psychiatric Association, Washington, DC. 
Aston, C., Jiang, L., Sokolov, B.P., 2005. Transcriptional profiling reveals evidence for signaling and 
oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. 
Mol Psychiatry 10, 309-322. 
Bale, T.L., Vale, W.W., 2003. Increased depression-like behaviors in corticotropin-releasing factor 
receptor-2 deficient mice: sexually dichotomous responses. J Neurosci 23, 5295-5301. 
43 
 
Benito, C., Tolon, R.M., Pazos, M.R., Nunez, E., Castillo, A.I., Romero, J., 2008. Cannabinoid CB2 
receptors in human brain inflammation. Br J Pharmacol 153, 277-285. 
Berton, O., Nestler, E.J., 2006. New approaches to antidepressant drug discovery: beyond 
monoamines. Nature Rev Neuroscience 7, 137-151. 
Bezard, E., Dovero, S., Belin, D., Duconger, S., Jackson-Lewis, V., Przedborski, S., Piazza, P.V., Gross, 
C.E., Jaber, M., 2003. Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors J Neurosci 
23, 999-1007. 
Bosker, F.J., Hartman, C.A., Nolte, I.M., Prins, B.P., Terpstra, P., Posthuma, D., van Veen, T., 
Willemsen, G., DeRijk, R.H., de Geus, E.J., Hoogendijk, W.J., Sullivan, P.F., Penninx, B.W., Boomsma, 
D.I., Snieder, H., Nolen, W.A., 2011. Poor replication of candidate genes for major depressive 
disorder using genome-wide association data. Mol Psychiatry 16, 516-532. 
Bradley, R.G., Binder, E.B., Epstein, M.P., Tang, Y., Nair, H.P., Liu, W., Gillespie, C.F., Berg, T., Evces, 
M., Newport, D.J., Stowe, Z.N., Heim, C.M., Nemeroff, C.B., Schwartz, A., Cubells, J.F., Ressler, K.J., 
2008. Influence of child abuse on adult depression: moderation by the corticotropin-releasing 
hormone receptor gene. Arch Gen Psychiatry 65, 190-200. 
Bröer, A., Tietze, N., Kowalczuk, S., Chubb, S., Munzinger, M., Bak, L.K., Bröer, S., 2006. The orphan 
transporter v7-3 (slc6a15) is a Na+-dependent neutral amino acid transporter (B0AT2). Biochem J 
393, 421-430. 
Bymaster, F.P., Lee, T.C., Knadler, M.P., Detke, M.J., Iyengar, S., 2005. The dual transporter inhibitor 
duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in 
depression. Curr Pharmaceut Design 11, 1475-1493. 
Cagniard, B., Balsam, P.D., Brunner, D., Zhuang, X., 2006. Mice with chronically elevated dopamine 
exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacol 31, 1362-
1370. 
Carola, V., Frazzetto, G., Pascucci, T., Audero, E., Puglisi-Allegra, S., Cabib, S., Lesch, K.-P., Gross, C., 
2008. Identifying molecular substrates in a mouse model of the serotonin transporter x environment 
risk factor for anxiety and depression. Biol Psychiatry 63, 840-846. 
Carroll, J.C., Boyce-Rustay, J.M., Millstein, R., Yang, R.J., Wiedholz, L.M., Murphy, D.L., Holmes, A., 
2007. Effects of mild early life stress on abnormal emotion-related behaviors in 5-HTT knockout mice. 
Behav. Genet. 37, 214-222. 
Caspi, A., Hariri, A.R., Holmes, A., Uher, R., Moffitt, T.E., 2010. Genetic sensitivity to the environment: 
the case of the serotonin transporter gene and its implications for studying complex diseases and 
traits. Am J Psychiatry 167, 509-527. 
44 
 
Caspi, A., Moffitt, T.E., 2006. Gene-environment interactions in psychiatry: joining forces with 
neuroscience. Nature Rev Neuroscience 7, 583-590. 
Caspi, A., Sugden, K., Moffitt, T.E., Taylor, A., Craig, I.W., Honalee, H., McClay, J., Mill, J., Martin, J.B., 
Braithwaite, A., Poulton, R., 2003. Influence of life stress on depression: moderation by a 
polymorphism in the 5-HTT gene. Science 301, 386-389. 
Causton, H.C., Quackenbusch, J., Brazma, A., 2003. Microarray Gene Expression Data Analysis: a 
beginner's guide. Blackwell Science, Oxford. 
Chen, Z.-Y., Jing, D., Bath, K.G., Ieraci, A., Khan, T., Siao, C.-J., Herrera, D.G., Toth, M., Yang, C., 
McEwen, B.S., Hempstead, B.L., Lee, F.S., 2006. Genetic variant BDNF (Val66Met) polymorphism 
alters anxiety-related behavior. Science 314, 140-143. 
Choudary, P.V., Molnar, M., Evans, S.J., Tomita, H., Li, J.Z., Vawter, M.P., Myers, R.M., Bunney, W.E., 
Akil, H., Watson, S.J., Jones, E.G., 2005. Altered cortical glutamatergic and GABAergic signal 
transmission with glial involvement in depression. PNAS 102, 15653-15658. 
Crawley, J., Goodwin, F.K., 1980. Preliminary report of a simple animal behavior model for the 
anxiolytic effects of benzodiazepines. Pharm Biochem Behav 13, 167-170. 
Cryan, J.F., Mombereau, C., Vassout, A., 2005. The tail suspension test as a model for assessing 
antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav 
Rev 29, 571-625. 
Danese, A., Caspi, A., Williams, B., Ambler, A., Sugden, K., Mika, J., Werts, H., Freeman, J., Pariante, 
C.M., Moffitt, T.E., Arseneault, L., 2010. Biological embedding of stress through inflammation 
processes in childhood. Mol Psychiatry XX, 1-2. 
Danese, A., Pariante, C.M., Caspi, A., Taylor, A., Poulton, R., 2007. Childhood maltreatment predicts 
adult inflammation in a life-course study. PNAS 104, 1319-1324. 
Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., 2008. From inflammation to 
sickness and depression: when the immune system subjugates the brain. Nature Rev Neurosci 9, 46-
57. 
Dawson, G.R., Tricklebank, M.D., 1995. Use of the elevated plus maze in the search for novel 
anxiolytic agents. TiPS 16, 33-. 
de Bodinat, C., Guardiola-Lemaitre, B., Mocaer, E., Renard, P., Munoz, C., Millan, M.J., 2010. 
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. 
Nature Rev Drug Discovery 9, 628-642. 
De Kloet, E.R., Joels, M., Holsboer, F., 2005. Stress and the brain: from adaptation to disease. Nature 
Rev Neuroscience 6, 463-475. 
Dell'Osso, B., Palazzo, M.C., Oldani, L., Altamura, A.C., 2011. The noradrenergic action in 
antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci Ther 17, 723-732. 
45 
 
Disner, S.G., Beevers, C.G., Haigh, E.A.P., Beck, A.T., 2011. Neural mechanisms of the cognitive model 
of depression. Nature Rev Neurosci 12, 467-477. 
Donovan, D.M., Miner, L.L., Perry, M.P., Revay, R.S., Sharpe, L.G., Przedborski, S., Kostic, V., Philpot, 
R.M., Kirstein, C.L., Rothman, R.B., Schindler, C.W., Uhl, G.R., 1999. Cocaine reward and MPTP 
toxicity: alteration by regional variant dopamine transporter overexpression. Mol Brain Res 73, 37-
49. 
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctot, K.L., 2010. A meta-
analysis of cytokines in major depression. Biol Psychiatry 67, 446-457. 
Drevets, W.C., Price, J.L., Furey, M.L., 2008. Brain structural and functional abnormalities in mood 
disorders: implications for neurocircuitry models of depression. Brain Struct Funct 213, 93-118. 
Duman, R.S., Li, N., Liu, R.-J., Duric, V., Aghajanian, G., 2012. Signaling pathways underlying the rapid 
antidepressant actions of ketamine. Neuropharmacol 62, 35-41. 
Duman, R.S., Monteggia, L.M., 2006. A neurotrophic model for stress-related mood disorders. Biol 
Psychiatry 59, 1116-1127. 
Duncan, L.E., Keller, M.C., 2011. A critical review of the first 10 years of candidate gene-by-
environment interaction research in psychiatry. Am J Psychiatry 168, 1041-1049. 
Fagiolini, M., Jensen, C.L., Champagne, F.A., 2009. Epigenetic influences on brain development and 
plasticity. Curr Opin Neurobiol 19, 207-212. 
Falzone, T.L., Gelman, D.M., Young, J.I., Grandy, D.K., Low, M.J., Rubinstein, M., 2002. Absence of 
dopamine D4 receptors results in enhanced reactivity to unconditioned, but not conditioned, fear. 
Eur J Neurosci 15, 158-164. 
Fernandez-Ruiz, J., Romero, J., Velasco, G., Tolon, R.M., Ramos, J.A., Guzman, M., 2006. Cannabinoid 
CB2 receptor: a new target for controlling neural cell survival? TiPs 28, 39-45. 
Flake, N.M., Zweifel, L.S., 2012. Behavioral effects of pulp exposure in mice lacking cannabinoid 
receptor 2. J Endodontics 38, 86-90. 
Gainetdinov, R.R., Jones, S.R., Fumagalli, F., Wightman, R.M., Caron, M.G., 1998. Re-evaluation of the 
role of the dopamine transporter in dopamine system homeostasis. Brain Res Rev 26, 148-153. 
Gaysina, D., Cohen, S., Craddock, N., Farmer, A., Hoda, F., Korszun, A., Owen, M.J., Craig, I.W., 
McGuffin, P., 2008. No association with the 5,10 -methylenetetrahydrofolate reductase gene and 
major depressive disorder: results of the depression case control (DeCC) study and a meta-analysis. 
Am J Med Genet Part B 147B, 699-706. 
Giros, B., Jaber, M., 1996. Hyperlocomotion and indifference to cocaine and amphetamine in mice 
lacking the dopamine transporter. Nature 379, 606-612. 
Grabe, H.-J., Schwahn, C., Appel, K., Mahler, J., Schulz, A., Spitzer, C., Fenske, K., Barnow, S., Lucht, 
M., Freyberger, H.-J., John, U., Teumer, A., Wallaschofski, H., Nauck, M., Völzke, H., 2010. Childhood 
46 
 
maltreatment, the corticotropin-releasing hormone receptor gene and adult depression in the 
general population. Am J Med Genet Part B 153B, 1483-1493. 
Gray, J.A., McNaughton, N., 2000. The Neuropsychology of Anxiety:  an enquiry into the functions of 
the septo-hippocampal system, 2nd ed. Oxford University Press, Oxford. 
Haddley, K., Vasiliou, A.S., Ali, F.R., Paredes, U.M., Bubb, V.J., Quinn, J.P., 2008. Molecular genetics of 
monoamine transporters: relevance to brain disorders. Neurochem Res 33, 652-667. 
Haenisch, B., Bilkei-Gorzo, A., Caron, M.G., Bönisch, H., 2009. Knockout of the norepinephrine 
transporter and pharmacologically diverse antidepressants prevent behavioral and brain 
neurotrophin alterations in two chronic stress models of depression. J Neurochem 111, 403-406. 
Haenisch, B., Bönisch, H., 2011. Depression and antidepressants: insights from knockout of 
dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther 129, 352-368. 
Haenisch, B., Linsel, K., Brüss, M., Gilsbach, R., Propping, P., Nöthen, M.M., Rietschel, M., Fimmers, 
R., Maier, W., Zobel, A., Höfels, S., Guttenthaler, V., Göthert, M., Bönisch, H., 2008. Association of 
major depression with rare functional variants in norepinephrine transporter and serotonin1A 
receptor genes. Am J Med Genet Part B (Neuropsychaitric Genetics) 150B, 1013-1016. 
Hall, F.S., Drgonova, J., Goeb, M., Uhl, G.R., 2003. Reduced behavioral effects of cocaine in 
heterozygous brain-derived neurotrophic factor (BDNF) knockout mice. Neuropsychopharmacol 28, 
1485-1490. 
Haller, J., Bakos, N., Rodriguiz, R.M., Caron, M.G., Wetsel, W.C., Liposits, Z., 2002. Behavioral 
responses to social stress in noradrenaline transporter knockout mice: Effects on social behavior and 
depression. Brain Res Bull 58, 279-284. 
Hariri, A.R., Mattay, V.S., Tessitore, A., Kolachana, B., Fera, F., Goldman, D., Egan, M.F., Weinberger, 
D.R., 2002. Serotonin transporter genetic variation and the response of the human amygdala. Science 
297, 400-403. 
Hasler, G., Northoff, G., 2011. Discovering imaging endophenotypes for major depression. Mol 
Psychiatry 16, 604-619. 
Heilig, M., Zachrisson, O., Thorsell, A., Ehnvall, A., Mottagui-Tabar, S., Sjögren, M., Asberg, M., 
Ekman, R., Wahlestedt, C., Agren, H., 2004. Decreased cerebrospinal fluid neuropeptide Y (NPY) in 
patients with treatment refractory unipolar major depression: preliminary evidence for association 
with preproNPY gene polymorphism. J Psychiat Res 38, 113-121. 
Helms, C.M., Gubner, N.R., Wilhelm, C.J., Mitchell, S.H., Grandy, D.K., 2008. D4 receptor deficiency in 
mice has limited effects on impulsivity and novelty seeking. Pharm Biochem Behav 90, 387-393. 
Holmes, A., Li, Q., Murphy, D.L., Gold, E., Crawley, J.N., 2003. Abnormal anxiety-related behavior in 
serotonin transporter null mutant mice: the influence of genetic background. Genes, Brain Behav 2, 
365-380. 
47 
 
Holsboer, F., 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacol 23, 
477-501. 
Ineichen, C., Sigrist, H., Spinelli, S., Lesch, K.-P., Sautter, E., Seifritz, E., Pryce, C.R., 2012. Establishing a 
probabilistic reversal learning test in mice: evidence for the processes mediating reward-stay and 
punishment-shift behaviour and for their modulation by serotonin. Neuropharmacol 63, 1012-1021. 
Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D.S., Quinn, K., Sanislow, C., Wang, P., 2010. 
Research domain criteria (RDoC): toward a new classification framework for research on mental 
disorders. Am J Psychiatry 167, 748-751. 
Jackson, I.J., Abbott, C.M., 2000. Mouse Genetics and Transgenics: a parictical approach. Oxford 
University Press, Oxford, p. xxiv+299. 
Jadavji, N., Deng, L., Leclerc, D., Malysheva, O., Bedell, B.J., Caudill, M.A., Rozen, R., 2012. Severe 
methylenetetrahydrofolate reductase deficiency in mice results in behavioral anomalies with 
morphological and biochemical changes in hippocampus. Mol Genetic Metab 106, 149-159. 
Jasinska, A.J., Lowry, C.A., Burmeister, M., 2012. Serotonin transporter gene, stress and raphe-raphe 
interactions: a molecular mechanism of depression. TINS XX, XX-XX. 
Jennings, K.A., Lesch, K.-P., Sharp, T., Cragg, S.J., 2010. Non-linear relationship between 5-HT 
transporter gene expression and frequency sensitivity of 5-HT signals. J Neurochem 115, 965-973. 
Jennings, K.A., Loder, M.K., Sheward, W.J., Pei, Q., Deacon, R.M.J., Benson, M.A., Olverman, H.J., 
Hastie, N.D., Harmar, A.J., Shen, S., Sharp, T., 2006. Increased expression of the 5-HT transporter 
confers a low-anxiety phenotype linked to decreased 5-HT transmission. J Neurosci 26, 8955-8964. 
Jones, S.R., Gainetdinov, R.R., Jaber, M., Giros, B., Wightman, R.M., Caron, M.G., 1998. Profound 
neuronal plasticity in response to inactivation of the dopamine transporter. PNAS 95, 4029-4034. 
Kang, A., Hao, H., Zheng, X., Liang, Y., Xie, Y., Xie, T., Dai, C., Zhao, Q., Wu, X., Xie, L., Wang, G., 2011. 
Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain 
distribution and anti-depression efficacy. J Neuroinflammation 8, 100. 
Kang, H.J., Adams, D.H., Simen, A., Simen, B.B., Rajkowska, G., Stockmeier, C.A., Overholser, J.C., 
Meltzer, H.Y., Jurjus, G.J., Konick, L.C., Newton, S.S., Duman, R.S., 2007. Gene expression profiling in 
prefronal cortex of major depressive disorder. J Neurosci 28, 13329-13340. 
Karg, K., MBurmeister, M., Shedden, K., Den, S., 2011. The serotonin transporter promoter variant (5-
HTTLPR), stress, and depression meta-analysis revisited. Arch Gen Psychiatry 68, 444-454. 
Kaster, M.P., Gadotti, V.M., Calixto, J.B., Santos, A.R.S., Rodrigues, A.L.S., 2012. Depressive-like 
behavior induced by tumor necrosis factor-a in mice. Neuropharmacol 62, 419-426. 
Kaufman, J., Yang, B.-Z., Douglas-Palumberi, H., Grasso, D., Lipschitz, D., Houshyar, S., Krystal, J.H., 
Gelernter, J., 2006. Brain-derived neurotrophic factor - 5-HTTLPR gene interactions and 
environmental modifiers of depression in children. Biol Psychiatry 59, 673-680. 
48 
 
Kendler, K.S., Hettema, J.M., Butera, F., Gardner, C.O., Prescott, C.A., 2003. Life event domensions of 
loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and 
generalized anxiety. Arch Gen Psychiatry 60, 789-796. 
Klempan, T.A., Sequeira, A., Canetti, L., Lalovic, A., Ernst, C., ffrench-Mullen, J., Turecki, G., 2009. 
Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the 
ventral prefrontal cortex of suicides with and without major depression. Mol Psychiatry 14, 175-189. 
Koetsier, G.C., Volkers, A.C., Tulen, J.H.M., Passchier, J., van den Broek, W.W., Bruijn, J.A., 2002. CPT 
performance in major depressive disorder before and after treatment with imipramine or 
fluvoxamine. J Psychiat Res 36, 391-397. 
Kohli, M.A., Lucae, S., Saemann, P.G., Schmidt, M.V., Demirkan, A., Hek, K., Czamara, D., Alexander, 
M., Salyakina, D., Ripke, S., Hoehn, D., Specht, M., Menke, A., Hennings, J., Heck, A., Wolf, C., Ising, 
M., Schreiber, S., Czisch, M., Müller, M.B., Uhr, M., Bettecken, T., Becker, A., Schramm, J., Rietschel, 
M., Maier, W., Bradley, B., Ressler, K.J., Nöthen, M.M., Cichon, S., Craig, I.W., Breen, G., Lewis, C.M., 
Hofman, A., Tiemeler, H., van Duijn, C.M., Holsboer, F., Müller-Myhsok, B., Binder, E.B., 2011. The 
neuronal transporter gene SLC6A15 confers risk to major depression. Neuron 70, 252-265. 
Krishnan, V., Han, M.-H., Graham, D.L., Berton, O., Renthal, W., Russo, S.J., LaPlant, Q., Graham, A., 
Lutter, M., Lagace, D.C., Ghose, S., Reister, R., Tannous, P., Green, T.A., Neve, R.L., Chakravarty, S., 
Kumar, A., A.J, E., Self, D.W., Lee, F.S., Tamminga, C.A., Cooper, D.C., Gershenfeld, H.K., Nestler, E.J., 
2007. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward 
regions. Cell 131, 391-404. 
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S.Z., Greenberg, B.D., Petri, S., Benjamin, J., Müller, C.R., 
Hamer, D.H., Murphy, D.L., 1996. Assosication of anxiety-related traits with a polymorphism in the 
serotonin transporter gene regulatory region. Science 274, 1527-1531. 
Levav-Rabkin, T., Blumkin, E., Galron, D., Golan, H.M., 2011. Sex-dependent behavioral effects of 
Mthfr deficiency and neonatal GABA potentiation in mice. Behav Brain Res 216, 505-513. 
Line, S.J., Barkus, C., Coyle, C., KJennings, K.A., Deacon, R.M.J., Lesch, K.P., Sharp, T., Bannerman, 
D.M., 2011. Opposing alterations in anxiety and species-typical behaviours in serotonin transporter 
overexpressor and knockout mice. Eur Neuropsychopharmacol 21, 108-116. 
Lopez-Leon, S., Croes, E.A., Sayed-Tabatabaei, F.A., Claes, S., Van Broeckhoven, C., Van Duijn, C.M., 
2005. The dopamine D4 reecptor gene 48-base-pair-repeat polymorphism and mood disorders: a 
meta-analysis. Biol Psychiatry 57, 999-1003. 
Lopez-Leon, S., Janssens, A.C.J.W., Gonsalez-Zuleoeta Ladd, A.M., Del-Favero, J., Claes, S.J., Oostra, 
B.A., van Duijn, C.M., 2008. Meta-analyses of genetic studies on major depressive disorder. Mol 
Psychiatry 13, 772-785. 
49 
 
Lopez, A.D., Mathers, C.D., Ezzati, M., Jamison, D.T., Murray, C.J., 2006. Global and regional burden of 
disease and risk factors, 2001: systematic analysis of population health data. Lancet 367, 1747-1757. 
Lu, A., Steiner, M.A., Whittle, N., Vogl, A.M., Walser, S.M., Ableitner, M., Refojo, D., Ekker, M., 
Rubenstein, J.L., Stalla, G.K., Singewald, N., Holsboer, F., Wotjak, C.T., Wurst, W., Deussing, J.M., 
2008. Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects 
on stress-coping behavior. Mol Psychiatry 13, 1028-1042. 
Lucki, I., Dalvi, A., Mayorga, A.J., 2001. Sensitivity to the effects of pharmacologically selective 
antidepressants in different strains of mice. Psychopharmacol 155, 315-322. 
MacQueen, G.M., Ramakrishnan, K., Croll, S.D., Siuciak, J.A., Yu, G., Young, L.T., Fahnestock, M., 2001. 
Performance of heterozygous brain-derived neurotropic factor knockout mice on behavioral 
analogues of anxiety, nociception, and depression. Behav Neurosci 115, 1145-1153. 
Mahley, R.W., Rall Jr, S.C., 2000. Apolipoprotein E: far more than a lipid transport protein. Annu Rev 
Genomics Hum Genet 1, 507-537. 
Manolio, T.A., 2010. Genomewide association studies and assessment of the risk of disease. N Engl J 
Med 363, 166-176. 
Martinovich, K., Manji, H., Lu, B., 2007. New insights into BDNF function in depression and anxiety. 
Nature Neurosci 10, 1089-1093. 
Mathews, T.A., Fedele, D.E., Coppelli, F.M., Avila, A.M., Murphy, D.L., Andrews, A.M., 2004. Gene 
dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced 
serotonin transporter expression. J Neurosci Methods 140, 169-181. 
Mayberg, H.S., 2003. Modulating dysfunctional limbic-cortical circuits in depression: towards 
development of brain-based algorithms for diagnosis and optimised treatment. Br. Med. Bull. 65, 
193-207. 
McGowan, P.O., Sasaki, A., D'Alessio, A.C., Dymov, S., Labonte, B., Szyf, M., Turecki, G., Meaney, M.J., 
2009. Epigenetic regulation of the glucocorticoid receptor in human brain associates with child 
abuse. Nature Neurosci 12, 342-348. 
Mickey, B.J., Zhou, Z., Heitzeg, M.H., Heinz, E., Hodgkinson, C.A., Hsu, D.T., Langenecker, S.A., Love, 
T.M., Pecina, M., Shafir, T., Stohler, C.S., Goldman, D., Zubieta, J.-K., 2011. Emotion processing, major 
depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry 68, 158-166. 
Miller, A.H., Maletic, V., Raison, C.L., 2009. Inflammation and its discontents: the role of cytokines in 
the pathophysiology of major depression. Biol Psychiatry 65, 732-741. 
Miller, R., Wankerl, M., Stalder, T., Kirschbaum, C., Alexander, N., 2012. The serotonin transporter 
gene-linked polymorphic region (5-HTTLPR) and cortisol stress reactivity: a meta-analysis. Mol 
Psychiatry XX, XX-XX. 
50 
 
Molina-Holgado, F., Lledo, A., Guaza, C., 1997. Anandamide suppresses nitric oxide and TNF-alpha 
responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 8, 1929-1933. 
Montanez, S., Owens, W.A., Gould, G.G., Murphy, D.L., Daws, L.C., 2003. Exaggerated effect of 
fluvoxamine in heterozygote serotonin transporter knockout mice. J Neurochem 86, 210-219. 
Murphy, S.E., Norbury, R., Godllewska, B.R., Cowen, P.J., Mannie, Z.M., Harmer, C.J., Munafo, M.R., 
2012. The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a 
meta-analysis. Mol Psychiatry XX, XX-XX. 
Murray, E.A., Wise, S.P., Drevets, W.C., 2011. Localization of dysfunction in major depressive 
disorder: prefrontal cortex and amygdala. Biol Psychiatry 69, e43-54. 
Nemeroff, C.B., 1996. The corticotropin-releasing factor (CRF) hypothesis of depression: New findings 
and new directions. Mol Psychiatry 1, 336-342. 
Nemeroff, C.B., Widerlov, E., Bissette, G., Walleus, H., Karlsson, I., Eklund, K., Kilts, C.D., Loosen, P.T., 
Vale, W., 1984. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in 
depressed patients. Science 226, 1342-1344. 
Oak, J.N., Oldenhof, J., van Tol, H.H.M., 2000. The dopamine D4 receptor: one decade of research. 
Eur J Pharmacol 405, 303-327. 
Onaivi, E.S., Ishiguro, H., Gong, J.-P., Patel, S., Meozzi, P.A., Myers, L., Perchuk, A., Mora, Z., 
Tagliaferro, P.A., Gardner, E., Brusco, A., Akinshola, B.E., Liu, Q.R., Chirwa, S.S., Hope, B., Lujilde, J., 
Inada, T., Iwasaki, S., Macharia, D., Teasenfitz, L., Arinami, T., Uhl, G.R., 2008. Functional expression 
of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in 
depression. Ann NY Acad Sci 1139, 434-449. 
Onaivi, E.S., Ishiguro, H., Sejal, P., Meozzi, P.A., Myers, L., Tagliaferro, P.A., Hope, B., Leonard, C.M., 
Uhl, G.R., Brusco, A., Gardner, E., 2006. Methods to study the behavioral effects and expression of 
CB2 cannabinoid receptors and its gene transcripts in chronic mild stress model of depression, in: 
Onaivi, E.S. (Ed.), Marijuana and Cannabinoid Research. Methods and Protocols Series: Methods in 
Molecular Medicine, Vol. 123. Humana Press, New York, pp. 291-298. 
Owens, M., Goodyer, I.M., Wilkinson, P., Bhardwaj, A., Abbott, R., Croudace, T., Dunn, V., Jones, P.B., 
Walsh, N.D., Ban, M., Sahakian, B.J., 2012. 5-HTTLPR and early childhood adversities moderate 
cognitive amd emotional processing in adolescence. PLoS one 7, e48482. 
Painsipp, E., Herzog, H., Sperk, G., Holzer, P., 2011. Sex-dependent control of murine emotional-
affective behavior in health and colitis by peptide YY and neuropeptide Y. Br J Pharmacol 163, 1302-
1314. 
Palin, K., Bluthe, R.-M., McCusker, R.H., Levade, T., Moos, F., Dantzer, R., Kelley, K.W., 2009. The type 
1 TNF receptor and its associated adapter protein, FAN, are required for TNFa-induced sickness 
behavior. Psychopharmacol 201, 549-556. 
51 
 
Parsey, R.V., Hastings, R.S., Oquendo, M.A., Hu, X., Goldman, D., Huang, Y.-y., Simpson, N., Arcement, 
J., Huang, Y., Ogden, R.T., Van Heertum, R.L., Arango, V., Mann, J.J., 2006. Effect of a triallelic 
functional polymorphism of the serotonin-transporter-linked promoter region on expression of 
serotonin transporter in the human brain. Am J Psychiatry 163, 48-51. 
Patel, A., Siegel, A., Zalcman, S.S., 2010. Lack of aggression and anxiolytic-like behavior in TNF 
receptor (TNF-R1 and TNF-R2) deficient mice. Brain Behav Immunity 24, 1276-1280. 
Perona, M.T.G., Waters, S., Hall, F.S., Sora, I., Lesch, K.-P., Murphy, D.L., Caron, M., Uhl, G.R., 2008. 
Animal models of depression in dopamine, serotonin and norepinephrine transporter knockout mice: 
prominent effects of dopamine transporter deletions. Behav Pharmacol 19, 566-574. 
Petronis, A., 2010. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. 
Nature 465, 721-727. 
Pogorelov, V.M., Rodriguiz, R.M., Insco, M.L., Caron, M.G., Wetsel, W.C., 2005. Novelty seeking and 
stereotypic activation of behavior in mice with disruption of the Dat1 gene. Neuropsychopharmacol 
30, 1818-1831. 
Porsolt, R.D., Le Pichon, M., Jalfre, M., 1977. Depression: a new animal model sensitive to 
antidepressant treatments. Nature 266, 730-732. 
Prut, L., Belzung, C., 2003. The open field as a paradigm to measure the effects of drugs on anxiety-
like behaviors: a review. Eur J Pharmacol 463, 3-33. 
Pryce, C.R., Azzinnari, D., Sigrist, H., Gschwind, T., Lesch, K.-P., Seifritz, E., 2012. Establishing a learned 
helplessness effect paradigm in C57BL/6 mice: behavioural evidence for emotional, motivational and 
cognitive effects of aversive uncontrollability per se. Neuropharmacol 62, 358-372. 
Pryce, C.R., Azzinnari, D., Spinelli, S., Seifritz, E., Tegethoff, M., Meinlschmidt, G., 2011. Helplessness: 
a systematic translational review of theory and evidence for its relevance to understanding and 
treating depression. Pharmacol Ther 132, 242-267. 
Pryce, C.R., Seifritz, E., 2011. A translational research framework for enhanced validity of mouse 
models of psychopathological states in depression. Psychoneuroendocrinology 36, 308-329. 
Ressler, K.J., Bradley, B., Mercer, K.B., Deveau, T.C., Smith, A.K., Gillespie, C.F., Nemeroff, C.B., 
Cubells, J.F., Binder, E.B., 2010. Polymorphisms in CRHR1 and the serotonin transporter loci: gene x 
gene x environment interactions on depressive symptoms. Am J Med Genet B Neuropsychiatric 
Genet 153B, 812-824. 
Romero-Zerbo, S.-Y., Garcia-Gutierrez, M.S., Suarez, J., Rivera, P., Ruz-Maldonado, I., Vida, M., 
Rodriguez de Fonseca, F., Manzanares, J., Bermudez-Silva, F.J., 2012. Overexpression of cannabinoid 
CB2 receptor in the brain induces hyperglycaemia and a lean phenotype in adult mice. J 
Neuroendocrinol 24, 1106-1119. 
52 
 
Rubenstein, M., Phillips, T.J., Bunzow, J.R., Falzone, T.L., Dziewczapolski, G., Zhang, G., Grandy, D.K., 
1997. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and 
methamphetamine. Cell 90, 991-1001. 
Rudin, M., 2009. Noninvasive structural, functional, and molecular imaging in drug development. 
Curr. Opin. Chem. Biol. 13, 1-12. 
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., 
Haapasalo, A., Nawa, H., Aloyz, R., Ernfors, P., Castren, E., 2003. Activation of the TrkB neurotrophin 
receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral 
effects. J Neurosci 23, 349-357. 
Schiepers, O.J.G., Wichers, M.C., Maes, M., 2005. Cytokines and major depression. Prog Neuro-
Psychopharmacol Biol Psychiatry 29, 201-217. 
Schol-Gelok, S., Janssens, A.C.J.W., Tiemeier, H., Liu, F., Lopez-Leon, S., Zorkoltseva, I.V., Axenovich, 
T.I., van Swieten, J.C., Uitterlinden, A.G., Hofman, A., Aulchenko, Y.S., Oostra, B.A., van Duijn, C.M., 
2010. A genome-wide screen for depression in two independent Dutch populations. Biol Psychiatry 
68, 187-196. 
Schuhmacher, A., Lennertz, L., Wagner, M., Höfels, S., Pfeiffer, U., Guttenthaler, V., Maier, W., Zobel, 
A., Mössner, R., 2012. A variant of the neuronal amino acid transporter SLC6A15 is associated with 
ACTH and cortisol responses and cognitive performance in unipolar depression. Int J 
Neuropsychopharmacol XX, XX-XX. 
Shelton, R.C., Claiborne, J., Sidoryk-Wegrzynowicz, M., Reddy, R., Aschner, M., Lewis, D.A., Mirnics, 
K., 2011. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in 
major depression. Mol Psychiatry 16, 751-762. 
Shioe, K., Ichimiya, T., Suhara, T., Takano, A., Sudo, Y., Yasuno, F., Hirano, M., Shinohara, M., Kagami, 
M., Okubo, Y., Nankai, M., Kanba, S., 2003. No association between genotype of the promoter region 
of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. 
Synapse 48, 184-188. 
Sibille, E., Arango, V., Galfalvy, H.C., Pavlidis, P., Erraji-Benchekroun, L., Ellis, S.P., Mann, J.J., 2004. 
Gene expression profiling of depression and suicide in human prefrontal cortex. 
Neuropsychopharmacol 29, 351-361. 
Sibille, E., Wang, Y., Joeyen-Waldorf, J., Gaiteri, C., Surget, A., Oh, S., Belzung, C., Tseng, G.C., Lewis, 
D.A., 2009. A molecular signature of depression in the amygdala. Am J Psychiat 166, 1011-1024. 
Siegel, J.A., Haley, G.E., Raber, J., 2012. Apolipoprotein E isoform-dependent effects on anxiety and 
cognition in female TR mice. Neurobiol Aging 33, 345-358. 
Siffert, W., 2001. Molecular genetics of G proteins and atherosclerosis risk. Basic Res Cardiol 96, 606-
611. 
53 
 
Smith, G.W., Aubry, J.-M., Dellu, F., Contarino, A., Bilezikjian, L.M., Gold, L.H., Chen, R., Marchuk, Y., 
Hauser, C., Bentley, C.A., Sawchenko, P.E., Koob, G.F., Vale, W., Lee, K.-F., 1998. Corticotropin 
releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and 
abberant neuroendocrine development. Neuron 20, 1093-1102. 
Soliman, F., Glatt, C.E., Bath, K.G., Levita, L., Jones, R.M., Pattwell, S.S., Jing, D., Tottenham, N., Amso, 
D., Somerville, L.H., Voss, H.U., Glover, G., Ballon, D.J., Liston, C., Teslovich, T., Van Kempen, T., Lee, 
F.S., Casey, B.J., 2010. A genetic variant BDNF polymorphism alters extinction learning in both mouse 
and human. Science 327, 863-866. 
Sommer, W.H., Lidström, J., Sun, H., Passer, D., Eskay, R., Parker, S.C.J., Witt, S.H., Zimmermann, U.S., 
Nieratschker, V., Rietschel, M., Margulies, E.H., Palkovitis, M., Laucht, M., Heilig, M., 2010. Human 
NPY promoter variation rs16147: T>C as a moderator of prefrontal NPY gene expression and negative 
effect. Human Mutation 31, E1594-E1608. 
Soskin, D.P., Carl, J.R., Alpert, J., Fava, M., 2012. Antidepressant effects on emotional temperament: 
toward a biobehavioral research paradigm for major depressive disorder. CNS Neurosci Ther 18, 441-
451. 
Spijker, A.T., van Rossum, E.F.C., 2009. Glucocorticoid receptor polymorphisms in major depression: 
focus on glucocortiocoid sensitivity and neurocognitive functioning. Ann NY Acad Sci 1179, 199-215. 
Steru, L., Chermat, R., Thierry, B., Simon, P., 1985. The tail suspension test: a new method for 
screening antidepressants in mice. Psychopharmacology (Berl). 85, 367-370. 
Stiedl, O., Radulovic, J., Lohmann, R., Birkenfeld, K., Palve, M., Kammermeier, J., Sananbenesi, F., 
Spiess, J., 1999. Strain and substrain differences in context- and tone-dependent fear conditioning of 
inbred mice. Behav Brain Res 104, 1-12. 
Sullivan, P.F., Consortium, M.D.D.W.G.o.t.P.G., 2012. A mega-analysis of genome-wide association 
studies for major depressive disorder. Mol Psychiatry XX, XX-XX. 
Sullivan, P.F., Neale, M.C., Kendler, K.S., 2000. Genetic epidemiology of major depression: review and 
meta-analysis. Am J Psychiatry 157, 1552-1562. 
Sun, H.-S., Kennedy, P.J., Nestler, E.J., 2013. Epigenetics of the depressed brain: role of histone 
acetylation and methylation. Neuropsychopharmacol 38, 124-137. 
Surget, A., Wang, Y., Leman, S., Ibarguen-Vargas, Y., Edgar, N., Griebel, G., Belzung, C., Sibille, E., 
2009. Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent 
model of depression and of antidepressant reversal. Neuropsychopharmacol 34, 1363-1380. 
Tasan, R.O., Khoi Nguyen, N., Weger, S., Sartori, S.B., Singewald, N., Heilbronn, R., Herzog, H., Sperk, 
G., 2010. The central and basolateral amygdala are critical sites of neuropeptide Y/Y2 receptor-
mediated regulation of anxiety and depression. J Neurosci 30, 6282-6290. 
54 
 
Taylor Tavares, J.V., Clark, L., Furey, M.L., Williams, G.B., Sahakian, B., Drevets, W.C., 2008. Neural 
basis of abnormal response to negative feedback in unmedicated mood disorders. Neuroimage 42, 
1118-1126. 
Thoeringer, C.K., Henes, K., Eder, M., Dahlhoff, M., Wurst, W., Holsboer, F., Deussing, J.M., 
Moosmang, S., Wotjak, C.T., 2012. Consolidation of remote fear memories involves cirticotropin-
releasing hormone (CRH) receptor type 1-mediated enhancement of AMPA receptor GluR1 signaling 
in the dentate gyrus. Neuropsychopharmacol 37, 787-796. 
Timpl, P., Spanagel, R., Sillaber, I., Kresse, A., Reul, J.M., Stalla, G.K., Blanquet, V., Steckler, T., 
Holsboer, F., Wurst, W., 1998. Impaired stress response and reduced anxiety in mice lacking a 
functional corticotropin-releasing hormone receptor 1. Nature Genet 19, 162-166. 
Touma, C., Gassen, N.C., Herrmann, L., Cheung-Flynn, J., Büll, D.R., Ionescu, I.A., Heinzmann, J.-M., 
Knapman, A., Siebertz, A., Depping, A.-M., Hartmann, J., Hausch, F., Schmidt, M.V., Holsboer, F., Ising, 
M., Cox, M.B., Schmidt, U., Rein, T., 2011. FK506 binding protein 5 shapes stress responsiveness: 
modulation of neuroendocrine reactivity and coping behavior. Biol Psychiatry 70, 928-936. 
Tyrka, A.R., Price, L.H., Gelernter, J., Schepker, C., Anderson, G.M., Carpenter, L.L., 2009. Interaction 
of child maltreatment with the corticotropin-releasing hormone receptor gene: Effects on 
hypothalamic-pituitray-adrenal axis reactivity. Biol Psychiatry 66, 681-685. 
Venihaki, M., Sakihara, S., Subramanian, S., Dikkes, P., Weninger, S.C., Liapakis, G., Majzoub, J.A., 
2004. Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation 
by stress and attenuation of some anxiety-like behaviours. J Neuroendocrinol 16, 411-422. 
Weaver, I.C.G., Cervoni, N., Champagne, F.A., D'Alessio, A.C., Sharma, S., Seckl, J.R., Dymov, S., Szyf, 
M., Meaney, M.J., 2004. Epigenetic programming by maternal behavior. Nature Neurosci 7, 847-854. 
Wellman, C.L., Izquierdo, A., Garrett, J.E., Martin, K.P., Carroll, J., Millstein, R., Lesch, K.-P., Murphy, 
D.L., Holmes, A., 2007. Impaired stress-coping and fear extinction and abnormal corticolimbic 
morphology in serotonin transporter knock-out mice. J Neurosci 27, 684-691. 
Williams, L.M., Gatt, J.M., Schofield, P.R., Olivieri, G., Peduto, A., Gordon, E., 2009. 'Negativity bias' in 
risk for depression and anxiety: Brain-body fear circuitry correlates, 5-HTT-LPR and early life stress. 
NeuroImage 47, 804-814. 
Willner, P., 1997. Validity, reliability and utility of the chronic mild stress model of depression: a 10-
year review and evaluation. Psychopharmacol 134, 319-329. 
Xu, F., Gainetdinov, R.R., Wetsel, W.C., Jones, S.R., Bohn, L.M., Miller, G.W., Wang, Y.-M., Caron, 
M.G., 2000. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. 
Nature Neurosci 3, 465-471. 
55 
 
Yamada, K., Iida, R., Miyamoto, Y., Saito, K., Sekikawa, K., Seishima, M., Nabeshima, T., 2000. 
Neurobehavioral alterations in mice with a targeted deletion of the tumor necrosis factor-a gene: 
implications for emotional behavior. J Neuroimmunol 111, 131-138. 
Young, J.W., Powell, S.B., Scott, C.N., Zhou, X., Geyer, M.A., 2011. The effect of reduced dopamine D4 
receptor expression in the 5-choice continuous performance task: Separating response inhibition 
from premature responding. Behav Brain Res 222, 183-192. 
Zhang, H.-L., Wu, J., Zhu, J., 2010a. The role of apolopoprotein E in Guillain-Barré syndrome and 
experimental autoimmune neuritis. J Biomed Biotech 2010, ID 357412. 
Zhang, T., Chen, Y., Liu, H., Zhou, Z., Zhai, Y., Yang, J., 2010b. Chronic unpredictable stress accelerates 
atherosclerosis through promoting inflammation in apolipoprotein E knockout mice. Thrombosis Res 
126, 386-392. 
Zimmermann, P., Brückl, T., Nocon, A., Pfister, H., Binder, E.B., Uhr, M., Lieb, R., Moffitt, T.E., Caspi, 
A., Holsboer, F., Ising, M., 2011. Interaction of FKBP5 gene variants and adverse life events in 
predicting depression onset: results from a 10-year prospective community study. Am J Psychiatry 
168, 1107-1116. 
Zörner, B., Wolfer, D.P., Brandis, D., Kretz, O., Zacher, C., Madani, R., Grunwald, I., Lipp, H.-P., Klein, 
R., Henn, F.A., Gass, P., 2003. Forebrain-specific trkB-receptor knockout mice: behaviourally more 
hyperactive than "depressive". Biol Psychiatry 54, 972-982. 
 
 
 
  
56 
 
Figure caption 
Figure 1. Schema to illustrate the inter-relationships between human and mouse studies aimed at 
increased understanding of the genetic aetio-pathophysiology of depression, and the overall 
approach used in this review. The methods of GWAS and CGCCS have been applied in humans to 
attempt to identify polymorphisms associated with depression (cG approach). Candidate genes have 
been studied in terms of their association with depression in interaction with environmental events, 
which can involve three major mechanisms: Polymorphism-specific predisposition to respond to the 
environment such that depression risk is increased (cG x E). Environmental events impacting on 
expression of a specific gene via altered transcription factor activity (E x cG), perhaps depending on 
the latter’s genotype.  Environmental events impacting on expression of a specific gene via altered 
epigenetic processes (E x epi-cG). The human descriptive evidence for the genetics of depression thus 
obtained has been applied to inform mouse experimental studies that are controlled and can yield 
cause-effect evidence. As in humans, studies of the mechanisms cG, cG x E, E x cG and E x epi-cG, 
need to be applied in the mouse models. The current review is organised according to the study 
methods included in this figure.  
 
 
 
Table 1. Summary of genes for which one polymorphism has been reported to exhibit relatively high association with depression   
                      
Gene        Risk polymorphism and biology  Study method  Reference   
                      
 
SLC6A15, Neuron-specific neutral amino acid transporter SNP: rs1545843 AA versus AG + GG  GWAS    Kohli et al., 2011 
Putative role in glutamate synthesis/transmission  AA associated with > reduction in hippocampal  
        volume in depressed vs control probands vs 
         AG/GG 
 
SLC6A4, Serotonin transporter (5-HTT)    2 x 22-23-bp insertion/deletion: deletion (S) CGCC, Meta-analysis  Lopez-Leon et al., 2008 
Integral membrane protein for pre-synaptic removal of  vs insertion (L) in promoter region (5-HTTLPR) 
serotonin from synaptic cleft     S associated with < 5-HTT activity   
 
DRD4, Dopamine receptor 4 (D4)    48-bp VNTR: 2 repeats vs 4, 7 repeats   CGCC, Meta-analysis  Lopez-Leon et al., 2005 
G protein-coupled receptor, activated by DA   in exon 3 
Inhibits adenylate cyclase, reducing cyclic AMP 
 
APOE, Apolipoprotein E      Two SNPs: rs429358 + rs7412   CGCC, Meta-analysis  Lopez-Leon et al., 2008 
Catabolism of triglyceride-rich lipoproteins   allele ε3 vs allele ε2  
 
GNB3, Guanine nucleotide-binding protein, beta polypeptide 3 SNP: rs5445 TT versus CT/CC   CGCC, Meta-analysis  Lopez-Leon et al., 2008 
Beta-3 subunit of GNB proteins (G-proteins), which integrate T associated with > G protein activity  
signals between receptors and effector proteins  
 
MTHFR, Methylenetetrahydrofolate reductase    SNP: rs1801133 TT versus TC + CC  CGCC, Meta-analysis  Lopez-Leon et al., 2008 
Enzyme for conversion of 5,10-MTHFR to 5-MTHFR.  TT associated with < MTHFR activity      but see Gaysina et al., 2008 
Low 5-MTHF (and low dietary intake of folic acid) 
leads to high homocysteine levels 
 
SLC6A3, Dopamine transporter (DAT1)    40-bp VNTR: rs28363170 9/10 repeats  CGCC, Meta-analysis  Lopez-Leon et al., 2008 
Integral membrane protein for pre-synaptic removal of  vs 10/10 repeats in untranslated 3’ region  
dopamine from synaptic cleft     9/10 associated with < DAT1 binding 
 
C5orf20, chromosome 5 open reading frame 20  SNP: rs12520799 TT vs AT + AA   GWAS + CGCC   Willis-Owen et al., 2006 
or DCNP1, dendritic cell nuclear protein-1 (DCNP1)  T encodes premature termination       Bosker et al., 2011 
Expressed in dendritic cells (antigen-presenting cells that of DCNP1 translation i.e. shorter protein 
activate T cells and B cells) 
 
TNF, Tumor necrosis factor     SNP: rs769178 C vs A    GWAS + CGCC   Bosker et al., 2011 
Pro-inflammatory cytokine 
 
NPY, Neuropeptide Y      SNP: rs16147 T vs C, T associated with < NPY GWAS + CGCC   Bosker et al., 2011 
Neurotransmitter in CNS and autonomic NS   SNP: rs16139 C vs T, C associated with < NPY   
         
SLC6A2, Norepinephrine transporter (NET)   SNP: rs5558 G vs T, G associated with > NET GWAS + CGCC   Haenisch et al., 2008 
Integral membrane protein for pre-synaptic removal of  Many SNPs each with low association       Bosker et al., 2011 
norepinephrine from synaptic cleft 
 
OPCML, Opioid binding protein/cell adhesion molecule-like SNP: rs12276491 AG vs AA   Family-based linkage analysis Schol-Gelok et al., 2010 
Member of immunoglobulin superfamily         + GWAS for linked regions 
Essential for coupling between opioid receptors and G proteins   
Co-localized with 5-HT, GABA 
 
FKBP5, FK506 binding protein 5     Five SNPs each with a polymorphism that Prospective CG study  Zimmermann et al., 2011 
Inhibitor of corticosteroid via glucocorticoid receptor  increases risk of depression in interaction with  
        trauma 
 
CRHR1, Corticotropin releasing hormone receptor 1  Multiple SNPs and one haplotype each with a  Retrospective CG study  Bradley et al., 2008 
Stress-responsive neuropeptide and neurotransmitter  polymorphism that increases risk of depression 
        In interaction with child abuse 
 
BDNF, Brain-derived neurotrophic factor   SNP: rs6265 A vs G, A associated with < BDNF Prospective CG study  Kaufman et al., 2006 
CNS neurotrophin      increases depression score in children in 
        Interaction with 5-HTTLPR S and maltreatment 
                      
 
 
Table 2. Summary of post mortem and translational studies of brain region-specific gene expression in depression  
                     
Gene or             Direction of 
Functional gene group    Study design   Brain region of interest  Expression change  Reference 
                     
Oligodendroglia/ Myelination    MDD vs Control  Temporal cortex, BA21  Down-regulation  Aston et al., 2005 
Axonal growth/Path finding  MDD: M/nM, S/N      Down-regulation      
Synaptic proteins   Microarray       Down-regulation    
Signal transduction protein kinases         Down-regulation    
Protein phosphatases           Down-regulation    
Other phosphoregulation-related         Down-regulation    
receptors            Down-regulation    
Chromatin/gene regulation          Down-regulation    
Protein synthesis/Degradation          Down-regulation    
Other             Down-regulation    
 
Transcriptional activation  MDD vs Control  vPFC, BA44   Down- or Up-regulation1 Klempan et al., 2009 
Ion transporter activity   MDD: nM, S       Down- or Up-regulation1   
Cell cycle control and division  Microarray       Down- or Up-regulation1   
GABA neurotransmission          Down- or Up-regulation1   
Glutamate neurotransmission           Down- or Up-regulation1   
Second messenger systems          Down- or Up-regulation1   
Tricarboxylic acid cycle   Microarray   vPFC, BA45   Down-regulation    
Cell cycle regulation           Down- or Up-regulation1   
Cell maturation            Down- or Up-regulation1   
Astrocyte    Microarray   vPFC, BA46   Down- or Up-regulation1   
Presynaptic proteins           Down- or Up-regulation1   
GABA neurotransmission          Down- or Up-regulation1   
Glutamate neurotransmission          Down- or Up-regulation1   
Cell maturation    Microarray   vPFC, BA47   Down- or Up-regulation1   
Synapse formation           Down- or Up-regulation1   
Tricarboxylic acid cycle           Down- or Up-regulation1   
 
Glutamate transporters  MDD vs Control  dACC, BA24   Down-regulation  Choudary et al., 2005 
Glutamine synthetase (GLUL)  MDD: M/nM, S/N      Down-regulation 
AMPA Glutamate receptor (GRIA1) Microarray       Up-regulation 
Glutamate transporters      dlPFC, BA9   Down-regulation 
Glutamine synthetase (GLUL)          Down-regulation 
Ionotropic glutamate receptors          Up-regulation 
GABAA receptor subunits          Up-regulation 
 
Stresscopin (UCN3)   MDD vs Control  dlPFC, BA9   Up-regulation   Kang et al., 2007 
Forkhead box 3 (FOXD3)  MDD: M/nM, S/N      Up-regulation 
Cannabinoid receptor 2 (CNR2)  Microarray       Up-regulation 
Intracellular signal transduction         Down- or Up-regulation1 
Extracellular signal transduction         Down- or Up-regulation1 
Cell cycle regulation           Down- or Up-regulation1 
Cell differentiation           Down- or Up-regulation1 
Apoptosis            Down- or Up-regulation1 
Chromatin/gene regulation          Down- or Up-regulation1 
Pro-inflammatory cytokine pathway         Up-regulation 
(incl. TNFRSF11B (TNF-family receptor), 
IFNAR1 (interferon receptor 1)) 
 
Y-box-binding protein 1 (YBX1)  MDD vs Control  ant. PFC, BA10   Up-regulation   Shelton et al., 2011 
Caspase-1 dominant-negative   MDD: nM, S/N/A         
Inhibitor pseudo-ICE (COP1)  Microarray       Up-regulation 
Apoptosis inhibitor (FKSG2)          Up-regulation 
Pro-inflammatory cytokine pathway 
(incl. IL-6, IFNγ, TNF)           Up-regulation 
Anti-inflammatory cytokine pathway 
(incl. IL-10)            Up-regulation 
 
Neuron structure/function, e.g.: Familial MDD vs Control 
Potassium channel tetramerisation + Mouse UCMS vs Control Amygdala   Up-regulation   Sibille et al., 2009 
domain containing 12 (KCTD12) MDD: M/nM, S/N  
Calcium channel, voltage-dependent, Microarray  
beta 2 subunt (CACNB2)          Up-regulation 
Calcium/calmodulin-dependent 
protein kinase II delta (CAMK2D)         Up-regulation 
Oligodendrocyte structure/function, e.g.: 
Plasma membrane proteolipid (PLLP)         Down-regulation 
Myelin-associated olgodendrocyte 
basic protein (MOBP)           Down-regulation 
G-protein coupled receptor 37 (GPR37)         Down-regulation 
                     
 
M/nM proband prescribed/not prescribed antidepressant medication at time of death 
Cause of death: S suicide, N natural, A accidental 
Table 3. Important depression psychopathologies, relevant human neuropsychological tests and corresponding mouse tests       
Psychopathology   Human Test       Mouse Test 
(relevant symptom)                    
Loss of pleasure/enjoyment  Emotional reactivity/sensitivity to positive (visual) stimuli Relative reactivity to palatable stimulus vs water 
of reward (Anhedonia)   e.g. photos of happy faces     e.g. sucrose preference test 
 
Loss of interest in/incentive for  Motivational reactivity to rewarding stimuli   Operant responding for palatable stimulus on effortful motivation 
reward  (Anhedonia)   e.g. performing cognitive task for money   schedule e.g. variable-interval, progressive ratio reinforcement 
  
High reactivity to aversive stimuli Emotional reactivity/sensitivity to negative (visual) stimuli Emotional reactivity to conditioned stimuli associated with aversion 
(Depressed mood)   e.g. photos of sad or fearful faces     e.g. fear conditioned freezing 
 
Stress uncontrollability   Emotional-cognitive reactivity to aversive uncontrollability Escape behaviour in two-way shuttle box  
(Depressed mood, Helplessness) e.g. Learned helplessness effect    e.g. Learned helplessness effect  
 
High negative feedback sensitivity Emotional-cognitive response to negative feedback  Emotional-cognitive response to negative feedback 
(Depressed mood, Catastrophization) e.g. Probabilistic reversal learning    e.g. Probabilistic reversal learning 
 
High bias to negative expectancy Emotional-cognitive reactivity to ambiguous stimuli  Emotional-cognitive reactivity to ambiguous stimuli 
(Depressed mood, Pessimistic outlook) e.g. Ambiguous-stimulus operant test    e.g. Ambiguous-stimulus operant test 
Fatigability    Physical effort to complete a manual task (grip strength) Effort-reward operant behaviour 
(Fatigue)    e.g. Grip strength test      e.g. Treadmill running to avoid aversive stimulus 
                   
Table modified from Pryce and Seifritz (2011) 
Table 4. Summary of ex vivo studies of brain region-specific gene expression in mice exposed to chronic stressors  
                      
Gene or              Direction of 
Functional gene group     Study design   Brain region of interest  Expression change  Reference 
                      
Brain-derived neurotrophic factor (Bdnf) CSD (SUS) vs Control  Nucleus accumbens  Up-regulation   Krishnan et al., 2007 
Adenylate cyclase isoform 7 (Adcy7)  Microarray       Up-regulation 
Cadherin 9 (Cdh9)            Up-regulation 
Histone deacetylase 2 (Hdac2)           Up-regulation 
Homeo box B3 (Hoxb3)            Up-regulation 
Runt-related transcription factor 1 (Runx1t1)         Up-regulation 
Phospholipase C gamma-2 (Plcg2)          Up-regulation 
Homer homolog 3 (Homer3)           Down-regulation 
 
Galanin (Gal)         Ventral tegmental area  Up-regulation 
Wingless-related MMTV site 2 (Wnt2)          Up-regulation 
NEL-2 like (Nell2)            Down-regulation 
 
Potassium channel tetramerisation  UCMS vs Control  Amygdala   Up-regulation   Sibille et al., 2009 
 domain containing 12 (Kctd12)    Microarray 
Calcium channel, voltage-dependent,   
beta 2 subunt (Cacnb2)            Up-regulation 
Calcium/calmodulin-dependent 
protein kinase II delta (Camk2d)          Up-regulation 
Oligodendrocyte structure/function, e.g.: 
Plasma membrane proteolipid (Pllp)          Down-regulation 
Myelin-associated olgodendrocyte 
basic protein (Mobp)            Down-regulation 
G-protein coupled receptor 37 (Gpr37)          Down-regulation 
 
Urocortin 3 (Ucn3)    3h physical restraint vs Control Paraventricular nucleus  Up-regulation   Venihaki et al., 2004 
      in situ hybridization  Amygdala   No change 
 
Cannabinoid receptor 2 (Cnr2)   UCMS vs Control  Whole brain    Up-regulation   Onaivi et al., 2008 
      RT-PCR 
 
Neuron-specific neutral amino acid  CSD vs Control   Hippocampus   Down-regulation  Kohli et al., 2011 
Transporter (Slc6a15)    in situ hybridization 
                      
 
CSD, chronic social defeat; SUS, susceptible to CSD 
UCMS, unpredictable chronic mild stress 
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